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Objective: In this thesis, we investigate the association between maternal factors, 
biophysical and biochemical markers and the delivery of small-for-gestational-age 
(SGA) neonates in the absence of preeclampsia (PE) at 11–13 weeks’ gestation. We 
evaluate their performance as predictors of SGA, both in isolation and combined, in 
an effort to develop a model for the prediction of SGA in the first trimester of 
pregnancy.   
 
Methods: Screening study in 1,536 SGA and 31,314 non-SGA pregnancies based on 
maternal characteristics, fetal nuchal translucency (NT) thickness, serum pregnancy-
associated plasma protein-A (PAPP-A) and free β-human chorionic gonadotrophin 
(β-hCG). We also measured mean arterial pressure (MAP), uterine artery pulsatility 
index (PI) and performed case-control studies for measurement of maternal serum 
concentration of placental growth factor (PLGF), placental protein 13 (PP13), A 
Disintegrin And Metalloprotease (ADAM12), Soluble endoglin (sENG) and thyroid 
hormones (thyroid stimulating hormone (TSH), free triiodothyronine (FT3) and free 
thyroxine (FT4)). Regression analysis was used to develop a model for the prediction 
of SGA.   
 
Results:  In the SGA group, uterine artery PI and MAP were increased, serum PAPP-
A, free β-hCG, PLGF, PP13, and ADAM12 and fetal NT were decreased while sENg 
and thyroid hormones were not significantly altered. At a false positive rate of 10%, 
the estimated detection rate by a combination of maternal factors and biophysical and 
biochemical markers at 11–13 weeks was 73% for SGA requiring delivery before 37 
weeks and 46% for those delivering at term.   
 
Conclusions:  Half of the pregnancies with SGA neonates in the absence of PE could 
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CHAPTER 1. INTRODUCTION 
 
1.1 OVERVIEW 
Fetal growth is dependent on a complex and dynamic interaction between the mother, 
the placental unit, and the fetus itself. Parental genetics determine a theoretical 
optimum weight which is subsequently modulated by the endocrine and nutritional 
environments in utero (Cetin & Alvino 2009).  
 
Fetal growth restriction is a term used to describe a pathological process which 
restricts the fetus from reaching its optimum genetic potential. Reduction in fetal 
growth has been associated with a plethora of different factors and has traditionally 
been considered under four main headings: maternal, fetal, environmental and 
placental (Table 1).  The pathophysiological mechanisms that potentially explain the 
above associations are multiple and are still subject of research and debate but many 
share a common endpoint which is an inability of the placenta to provide adequate 
oxygen and nutrient transfer to the fetus (Lackman et al., 2001, Battalia & Regnault 
2001, Cetin & Alvino 2009).    
 
Growth restriction secondary to placental insufficiency is considered to be a major 
contributor to perinatal morbidity and mortality, being responsible for 50% of perinatal 
deaths occurring preterm and 20% at term (Kady & Gardosi 2005). In addition, it is 
well recognized that growth restricted fetuses carry increased risks of metabolic, 
cardiovascular and neurological diseases into adult life (Gluckman et al., 2008). It 
commonly presents in combination with the maternal syndrome of preeclampsia but 









fetal growth restriction manifests early in pregnancy, marked abnormalities of 
placental function are typically evident. Usually this process takes a recognized 
course of progression with gradual changes in the blood flow pattern through the 
placenta and can be detected via Doppler ultrasound (Baschat 2005). In near-term 
FGR these abnormalities are far more subtle and may escape clinical detection (Miller 
et al., 2008).  
 
Small for gestational age is a descriptive term which denotes that a fetus weighs less 
than a defined standard of normality, usually a population average for a given 
gestation. The SGA group is used in an attempt to identify fetuses that are at 
increased risk of growth restriction, however, its sensitivity as a marker varies and 
studies have shown it can be as low as 30% (Alberry & Soothil 2007). Despite this 
poor correlation, SGA fetuses have been found to be at increased risk of adverse 
perinatal outcomes and their identification prenatally has been shown to improve fetal 
outcomes (Figueras & Gratacos 2014).  The SGA group has been used traditionally 
as an outcome measure in studies because of its association with FGR and because 
it is easily available from birth records.  
 
In this thesis we aim to investigate different modalities in an attempt to develop a 
screening tool for fetal growth restriction. Our study design is based on the use of the 
birth of an SGA neonate as an outcome measure but we also discuss the merits of 
using alternative definitions that might perform better as markers of FGR. We 
examine risk factors for placental disease from maternal history as well as a variety 
of biophysical markers, such as the measurement of Blood Pressure (BP), uterine 
artery Doppler (UAD), and biochemical markers, such as placental associated protein 
A (PAPP-A), placental growth factor (PLGF) or Placental protein 13 (PP13). 
Ultimately we use multivariate regression analysis of the above factors to develop a 











1.2 EPIDEMIOLOGY OF FETAL GROWTH RESTRICTION   
 
1.2.1 Defining abnormal fetal growth 
 
Abnormal fetal growth has traditionally been a great challenge to define both in clinical 
practice and research and hence a variety of different definitions are in use.  
Historically adverse fetal outcomes were observed in association with low 
birthweights and hence early definitions of abnormal weight considered a single 
weight cut-off independent of gestation (Table 1.2). This was usually the 2.5kg, 1.5kg 
or 1kg limit. This definition is now considered out-dated in favour of gestation-specific 
weight cut-offs since it allows differentiation of the effects of prematurity and fetal 
weight on perinatal morbidity and mortality (WHO promoting optimal fetal 
development 2006; Zhang et al., 2010) . Commonly used cut-offs are that of the 3rd, 
5th or 10th centiles of the birthweight distribution at every gestation. 
 
Birthweight normograms have been derived from large cross-sectional population 
studies that include all births at all gestations without excluding high-risk pregnancies 
(Williams et al., 1982; Alexander et al., 1996; Zhang et al., 2007), or can be derived 
by a selected “normal” population that excludes pregnancies with complications that 
are known to affect fetal growth (Ananth et al., 2009). A fetus that falls below this 
specified centile is labeled as Small for Gestations Age (SGA) and carries increased 






























 Maternal low birthweight 
 Low maternal weight gain 
 Maternal age <16 
 Low socio-economic status 
 Parity 
 Medical disorders 
 Chronic hypertension 
 Pre-eclampsia 
 Systemic Lupus Erythematosus 
 Diabetes with vasculopathy 
 Renal disease 
Placental factors 
 Abnormal placentation 
 Chronic abruption 
 Chronic inflammatory conditions 
(villitis) 
 Single UA 
 Velamentous cord insertion 
 Placental haemangioma 
 Confined placental mosaicism 
Fetal factors 
 Chromosomal anomalies 
 Genetic conditions 
 Congenital malformations 
 Intrauterine infections 
 Multiple pregnancy 
Environmental factors 
 Drug use – smoking, alcohol, 
illicit drugs 
 High altitude 
 Irradiation 









Table 1.2 Common definitions used in literature to define a reduced fetal weight 
 
 
The SGA group will include constitutionally small fetuses that are theoretically at no 
higher risk of adverse outcomes than an Appropriate for Gestational Age (AGA) 
neonate and those that are pathologically growth restricted. At the same time, a 
proportion of true growth restricted fetuses might not drop below the centile cut-off 
but still suffer from the pathological process. 
 
The inability of the previously mentioned definition to optimally distinguish 
pathological from physiological smallness led researchers into proposing optimized 
techniques for defining abnormal fetal growth. The following two main variations have 
emerged: the use of ultrasound-derived fetal growth curves as opposed to curves 
derived from birthweight data and the adjustment for maternal characteristics. 
Different studies have examined their use independently or combined in what is 




 Single weight cut-offs independent of gestation  
o Low birth weight - <2.5kg 
o Very low birth weight - <1.5kg 
 Gestation specific centiles (<3rd, <5th,<10th centile)  
o Based on unselected populations 
o Based on selected populations 
o Based on ultrasound derived curves 
 Cross-sectional 
 longitudinal 
 Customized centiles (Ultrasound derived gestation-specific centiles 









Ultrasound versus population derived centiles 
 
Studies showed improved correlation between the ultrasound-defined SGA fetuses 
and perinatal morbidity and mortality (Figueras et al., 2007) compared with population 
standards. This was initially attributed to the customization process, however, a 
recent large population-based study using strict inclusion criteria and excluding 
pathological pregnancies delivering preterm produced very similar growth curves with 
ultrasound based centiles (Poon et al., 2012). Consequently, it is argued that 
exclusion of pathological preterm gestations either by strict selection or by using an 
ultrasound derived growth curve in order to define normal limits of birthweight appears 
to be the key in defining a true “normal” population. The fetuses that are classified as 
SGA by these methods have been shown to correlate better with perinatal morbidity 
and mortality compared with old population derived curves that have not excluded 
pathological preterm pregnancies (Groom et al., 2007; Hutcheon et a.l, 2008; Poon 
et al., 2012).  
 
Adjustment for maternal characteristics 
 
Birthweight varies with maternal characteristics (e.g. ethnicity, parity, parental height) 
and according to the “customized centile” school of thought, a birthweight centile that 
corrects for these characteristics is likely to differentiate better between physiological 
and pathological size (Gardosi et al., 1992). The customized centile however also 
uses an ultrasound derived curve to define the optimum fetal weight for any gestation. 
The performance of the customized centile has been consistently shown to be 
superior to population derived methods, however, recent data attributes this effect to 
the exclusion of pathological preterm pregnancies and not to the adjustment for 
maternal characteristics (Hutcheon et al., 2008; Poon et al., 2012). The debate as to 










In this thesis, we have used the weights from live births of a well-controlled normal 
population to define a birthweight standard for use in our prediction model. 
 
An improved definition of FGR 
 
The ideal definition of abnormal growth is the one that reflects pathology and has the 
ability to best predict adverse fetal outcome in the form of perinatal morbidity and 
mortality. A definition of fetal growth restriction relying solely on a deviation from a 
size norm can fall short in identifying truly affected fetuses (Zhang et al., 2010). 
Advances in the definition of FGR have been attempted by the integration of a variety 
of functional markers such as umbilical, uterine and middle cerebral artery blood flow 
measured by Doppler ultrasound or maternal serum biomarkers (Figueras & 
Gratacos, 2014). Our study design did not allow an opportunity for evaluating 
placental function in the third trimester and hence we have used as our primary 
outcome measure the birth of an SGA infant below the 5th centile adjusted for 
gestation as a proxy for FGR. In the final chapter of this thesis we discuss the potential 
value of using an improved definition of FGR, critically evaluate relevant studies and 
make suggestions about future study design. 
 
1.2.2 Incidence of SGA and associated adverse outcomes  
 
The incidence of SGA will depend on the definition used and traditionally ranges 
between 3%-10%.There is an established strong correlation between reduced fetal 
weight and adverse pregnancy outcomes and there is also an established correlation 
between SGA and later life complications (Table 1.3). Estimations describe a rate of 
around 30 million babies per year are born with intrauterine growth restriction in 
developing countries with developed countries expectedly having about 5 million. The 
highest incidence of SGA lies in Asia (75%), mainly South East Asia, followed by 










The association of placental insufficiency and antepartum stillbirth is well established 
but the degree of correlation varies considerably within the literature. The lancet 
reports a total number of 36300 stillbirths in high-income countries in 2008, 
corresponding to around 5/1000 total births. On analysing the causation of stillbirths 
in this high-income setting, 32% of stillbirths can be attributed to Fetal Growth 
Restriction (Lawn 2011). In the most recent CEMACE report (2009) 19% of stillbirths 
at any gestation are associated with reduced fetal growth, however, many authors 
believe that this number is a modest estimate and evidence suggests that a large 
proportion of stillbirths defined as “unexplained” are actually secondary to growth 
restriction (Vergani et al., 2008; Korteweg et al., 2008; Stillbirth Collaborative 
Research Network Writing Group 2011). In another study it is shown that by using a 
new classification for stillbirths taking into account fetal weight shows 43% of fetuses 
had a Birthweight below the 10th centiIe (Gardosi et al., 2005), while another study 
examining stillbirths without any fetal anomalies found the birthweight was below the 
10th percentile in 71.8% of those found at <32 weeks’ gestation (poon et al., 2012).  
When examining predictors of stillbirth, prior delivery of a growth restricted infant is 
among the strongest risk factors for stillbirth, comparable to the history of prior 










Table 1.3 Perinatal complications of fetal growth restriction (Palloto& Kilbride, Clinical 
Obstetrics and Gynaecology 2006) 
 
 
 Perinatal mortality higher among term and preterm fetuses with reduced 
growth 
 Intrapartum hypoxia and distress 
 Increased rates of Hypoxic Ischaemic Encephalopathy (HIC) 
 Increased rates of seizures 
 Increased effects of prematurity complications in preterm SGA 
 Increased rates on Necrotizing Enterocolitis (NEC) 
 Increased rates of Respiratory Distress Syndrome (RDS) 
 Increased intraventricular hemorrhage 
 Retinopathy of prematurity 




 Reduced immune function and more susceptible to sepsis 
 Coagulopathy 
 Bronchopulmonary dysplasia 
 Late life complications 
 reduced physical growth 
 reduced neurodevelopmental capacity 
 reduced school performance 
 association with metabolic syndrome and type 2 diabetes 




Besides the association with fetal death, SGA fetuses are at higher risk of a variety 
of perinatal complications both during labour and at the early neonatal period. 
Perinatal mortality in SGA infants is 10-20 times higher than that of an AGA infant 
(McIntire et al., 1999; Revev et al., 2003). SGA fetuses are more likely to experience 
Intrapartum distress resulting in Hypoxic injury. They have higher rates of meconium 









cord PH (<7.0). Subsequently, SGA born neonates have higher rates of complications 
such as Hypoxic-ischaemic encephalopathy (HIE), Respiratory distress syndrome 
(RDS), Necrotizing Enterocolitis (NEC) and intraventricular hemorrhages (IVH). 
Prematurity and smallness have a cumulative effect on the risk of all perinatal 
complications (Regev et al., 2004).  
 
A growing body of research is revealing links of the consequences of fetal growth 
restriction in utero with later-life complications. It is hypothesized that the adaptations 
that take place as a result of the adverse intrauterine environment imprint permanent 
changes on the metabolic, cardiovascular and neurological programming of neonates 
and manifest as adult diseases (Gluckman et al., 2008).  More specifically smallness 
at birth and infancy is associated with increased rates of coronary heart disease, 
stroke, type 2 diabetes, adiposity, the metabolic syndrome and osteoporosis in later 
life and these results have been consistently replicated in studies and are 
independent of environmental risk factors in adults (Fall et al., 1995; Phillips et al., 
1994; Bateson et al., 2004; Cooper et al., 1997; Barker et al., 2012).  
 
1.3 AETIOLOGY OF FETAL GROWTH RESTRICTION 
 
The aetiological mechanism of growth restriction has traditionally been attributed to 
defective placentation during early stages of pregnancy. Classic histological findings 
have been described in a variety of studies such as shallow endovascular trophoblast 
invasion and inadequate uteroplacental artery remodeling and are seen both in SGA 
pregnancies and pre-eclampsia (PE). Hence the belief that both conditions share 
common pathophysiological pathways with different clinical manifestations.  
 
The extent to which the two conditions overlap and the reasons why some 









insufficiency is still unclear. When considering the aetiological factors of growth 
restriction and pre-eclampsia the approaches vary with some studies examining 
isolated cases while others investigate the syndrome of placental insufficiency with 
varying degrees of overlap between PE and FGR. A multifactorial model for the 
pathogenesis of placental insufficiency appears to be the most representative way to 
explain the pathophysiology of the disease (Figure 1.1).  
 
Figure 1.1 A simplified schematic representation of the factors that have been shown 
to contribute to the pathophysiology of placental disease resulting in PET and/or FGR. 












The process of normal placentation will be summarized below in order to illustrate the 
different theories around the aetiology of inadequate placentation. 
1.3.1 Normal placentation 
 
From the first week after conception, the differentiating cells of the developing embryo 
form an outer layer of trophoblast cells which will eventually contribute to the fetal 
component of the placenta. Once trophoblast cells come in contact with the 
endometrium (apposition) the process of implantation begins. From the maternal 
interface uterine stroma and endometrial cells begin a cascade of changes such as 
influx of Natural Killer cells, increase mitotic activity and alteration in stroma cell 
morphology, collectively called decidualization in order to facilitate further 
implantation of the embryo (Eide et al., 2005; Johnson Essential reproduction 2000). 
Decidualized endometrial cells will form part of the maternal component of the 
placenta. At the moment of contact metalloproteases (protease enzymes) dissolve 
the zona pellucida surrounding the trophoblast thus allowing the multiple adhesion 
molecules expressed on the surface of the trophoblast cells to adhere to the decidua 
(Cohen et al., 2007). Besides dissolution of surrounding matrix trophoblast cells 
actively move through endometrial cells with the help of cytoskeletal microfilaments 
(Burrows et al., 1996). 
 
Initial exchange of nutrients between the developing embryo and mother occurs from 
lacunae, small clefts communicating with maternal endometrial sinusoids. These 
lacunae are the precursors of the intervillous space which facilitates circulation of 
maternal blood through the placenta. Two characteristics of the placenta define its 
ability to effectively exchange gasses and nutrients between fetus and mother. From 









for such exchange to occur. Primary stem villi arise after day 13 or embryonic life and 
branch out into secondary and eventually tertiary villi that occupy the intervillous 
space and form the final placenta structure. From the maternal interface trophoblastic 
invasion of maternal blood vessels (haemochorial placentation) allows maternal blood 
to enter the intervillous space and bathe the chorionic villi with maternal blood. This 
process of invasion of maternal spiral arteries and their conversion from high 
resistance vessels to wider bore capacitance vessels is thought to be crucial in the 
correct development of the placental circulation and has been a particular focus of 
research. As will be discussed further inadequate invasion has been implicated in the 
development of placental insufficiency and all its clinical manifestations of 
preeclampsia and growth restriction. By 12 weeks the placenta has completed its 
architectural development and subsequently only increases in size while conversion 
of spiral arteries is thought to be complete between 16-18 weeks (Pijnenborg et al., 
1980). 
 
Remodeling of spiral arteries 
 
Uterine vasculature begins from the two uterine arteries traversing the lateral walls of 
the uterus in an upward direction with a small contribution from the ovarian arteries 
directed downwards. Each uterine artery supplies lateral branches that immediately 
enter the uterus and give off tortuous anterior and posterior arcuate divisions, which 
run circumferentially in the myometrium. Each arcuate artery throughout its course 
gives off numerous radial branches. Once these vessels reach the endometrial level, 
they branch into the basal arteries and spiral arteries, which support the specialized 
functions of each layer. The basal arteries are not responsive to hormones; they 
support the basal endometrial layer, which provides the proliferative cells for 
endometrial growth. The spiral arteries supply the endometrial layer and possess 
many unique characteristics allowing them to adapt to the changing environment of 









on the mechanism of placentation indicate a two-stage process of physiologic 
remodeling of the spiral arteries during gestation involving a decidua-associated and 
a trophoblast-associated stage (Brosens et al., 2011; Table 1.4).  
 
Initial signs of the decidualization changes have been observed independently of 
cellular interactions with invasive cytotrophoblasts and include endothelial basophilia, 
expression of endothelial activation markers and vacuolization, followed by dilation, 
muscular hypertrophy, disorganization, and fibrinoid change (Craven et al., 1998). It 
is thought that decidualized endometrium can modulate trophoblast function by 
altering expression of regulatory factors such as metalloproteinases, cytokines, 
surface integrins, and major histocompatibility complex molecules (Brosens et al., 
2002) . 
 
The interstitial invasion of extravillous trophoblast proceeds from cytotrophoblast at 
the tips of the anchoring villi and can be seen in the decidual part of the spiral arteries 
from around 4 weeks. From 8 weeks of gestation onward, myometrial invasion ensues 
and peaks between 9 and 12 weeks (Aplin et al., 1988).  Interstitial trophoblast 
penetration proceeds with minimal tissue destruction and invading cells preferentially 
home toward the spiral arteries and encircle them to reach the arterial media (Kam et 
al., 1999; Pijnenborg et al., 1983). Invasion of the spiral arteries is evident in 
histological studies by amorphous acidophilic “fibrinoid” deposits in the arterial wall 
embedded with cytotrophoblastic cells. Finally, the complete absence of the musculo-
elastic structure, enlarged funnel-shaped luminal diameter and re-endothelialization 
define a “physiologically changed” spiral artery or uteroplacental vessel (Pinjenborg 
et al., 1983; Brosens, 1988).  
 
Characteristics of normal trophoblastic invasion include invasion of junctional and 
myometrial segments of the spiral arteries and a higher invasion distribution in the 









1995). The term “deep placentation” has been used to describe the observed 
complete transformation of the decidual and myometrial segments of approximately 
100 spiral arteries (Brosens et al., 2011). 
 
  
Table 1.4 Steps of spiral artery remodeling (Brosens et al., 2011) 
 
 
1 Initial stage of decidua-associated remodeling, 
2 intra-arterial trophoblast migration, 
3 intramural invasion and trophoblast-associated remodeling,  
4 Re-endothelialization and other maternal-induced changes. 
 
 
1.3.2 Mechanisms of abnormal placentation 
 
Histopathological examination of placenta beds was first performed in cases of pre-
eclampsia with or without fetal growth restriction and was consistent with an absence 
of the previously described physiological changes of spiral artery transformation 
primarily in the junctional zone and myometrial layers (Brosens et al., 1972).  
Junctional zone spiral arteries appeared to be of smaller caliber with a thicker lumen, 
muscular walls and more densely distributed (Starzyk et al., 1997; Pijnenborg et al., 
1991). Hence a deduction was made that the defect lies in trophoblastic invasion. 
Further findings of atherosis of the non-invaded vessels with characteristics of 
necrosis, fibrin deposition and lipophage infiltration of the vessel wall were described 
(Robertson et al., 1967; Brosens & Renaer 1972). Similar histological findings have 
been described also in placentas of pregnancies with growth restriction in the 
absence of preeclampsia (Sheppard & Bonnar 1981; Hustin et al., 1983; De wolf et 









spiral arteries in cases of growth restriction without preeclampsia (Khong et al., 1986; 
Gerretsen et al., 1981).  
 
Several pathophysiological mechanisms have been associated with the above 
findings and include immune maladaptation, disturbed blood flow stress, impaired 
decidualization of myometrial spiral arteries or exaggerated inflammatory response 
among others (Chaiworapongsa et al., 2014). However, evidence suggests that 
impaired conversion of spiral arteries is present in a variety of different obstetric 
syndromes such as miscarriage, intrauterine death, placental abruption, premature 
rupture of membrane and preterm labour (Ball et al., 2006, Brosens et al., 2011, 
Khong et al., 1987). Hence inadequate spiral artery transformation cannot be deemed 
as the sole aetiological factor behind placental insufficiency but rather as a probable 
common step in a potentially complicated multi-step aetiological mechanism.  
 
The greatest hindrance in determining causation is the fact that placental insufficiency 
has its pathogenic origins in the first trimester and as such causal relationships 
inferred from late-gestation decidual pathologies are inherently unreliable. An 
overview of the prevailing areas of investigation will be presented below. 
 
Placental angiogenesis and its pathophysiology 
 
Placental angiogenesis is a tightly controlled process that depends on many 
stimulating and inhibiting factors. The key signaling system that regulates proliferation 
and migration of endothelial cells forming the basis of any vessel are vascular 
endothelium growth factors (VEGF) and their receptors. The biological significance of 
the effect of such system is defined by the ratio of different isoforms present 
(Karamysheva 2008). In addition to VEGF, a variety of other signaling systems have 
been found to co-regulate angiogenesis. Such systems are tyrosine kinase receptor 










The VEGF family includes factors VEGF-A, B, C & D, and Placenta growth factor 
(PlGF). There are three VEGF family receptors, known as Flt-1, KDR, and Flt-4, as 
well as a soluble form of Flt-1(sFLT-1) (Huckle & Roche 2004; Thomas et al., 2007; 
De Falco 2012). Immunohistochemical studies on the expression patterns of VEGF, 
PLGF, and their receptors in the placenta, as well as maternal serum levels 
throughout pregnancy, suggest an important role in villous angiogenesis (Cerdeira & 
Karumanchi 2012). Kaufmann et al., showed a correlation between reducing 
expression of VEGF and increasing expression of PLGF with the transition from 
branching to non-branching angiogenesis of the placental villi (Kaufman et al., 2003).  
 
A variety of studies have associated the interrelationships of VEGF factors and 
receptors throughout different gestations with various physiological processes of 
placental implantation and development (Clark et al., 1998; Helske et al., 2001; Demir 
et al., 2009) and as such, their role in placentation is beyond doubt significant. Other 
factors implicated in early angiogenesis include the angiopoietin family and its 
receptors Tie-2, PDGF, TGF-b  and Endoglin (Eng) which is a co-receptor for 
transforming growth factor (TGF)-b 1 and 3 (Cheifetz et al.,1992). They are thought 
to be involved in the maturation and stabilization of primitive endothelial tubes (Kayisli 
et al., 2006; Seval et al., 2008; Dunk et al., 2000).  
 
At the same time, a variety of other hormones and pregnancy-specific growth factors 
have been evaluated and found to have pro-angiogenic properties. Zygmunt et al., 
showed that physiological concentrations of β-hCG significantly increased in-vitro 
capillary formation and migration of endothelial cells (Zygmunt et al., 2002). While in 
another study insulin-like growth factor-II (IGF-II) was found to have a potential role 










Subsequently the focus of research extended in trying to detect and interpret 
differences between patterns of expression of such markers in pathological cases of 
preeclampsia and fetal growth restriction. sFLT-1 a factor with anti-angiogenic 
properties has been consistently shown to be increased in cases with preeclampsia 
while VEGF and PLGF, both vascular stabilizing factors, have been found to be 
reduced, hence supporting the theory of antagonism of VEGF and PlGF resulting in 
the appearance of hypertension (Buhimschi et al., 2005; Levine et al., 2005; Aggarwal 
et al., 2006, Maynard et al., 2008). Many of the imbalances between these factors are 
thought to be the causative factors of the vasculopathic syndrome of pre-eclampsia 
resulting in endothelial damage with all its consequences.  
 
Concentrations of most markers appear to be maximally increased late in gestation 
as clinical symptoms develop. In the case of placental insufficiency without 
hypertension, there is the absence of endothelial damage and its clinical 
manifestations and hence investigation into these markers in normotensive growth 
restricted pregnancies has shown less definitive findings. Modest increase in serum 
concentrations of sFlt-1 have been found in normotensive growth restriction 
(Tsatsaris et al., 2003), but equally, a difference was not demonstrated in another 
study (Shibata et al., 2005). Decreased levels of oxygen tension were hypothesized 
to result in premature maturation of vessels and contribute to the abnormal 
development of villous trees (associated with non-branching angiogenesis) in another 
study (Mayhew et al., 2004).  
 
A natural consequence of the observations that changes in the serum/plasma 
concentrations of angiogenic and anti-angiogenic factors can be detected prior to the 
clinical recognition of the disease is that assays for such factors may be useful in the 
risk assessment for PE and FGR. Indeed, several studies have addressed this issue 
by investigating an array of different markers in isolation or in combination with other 









flow. We review a variety of biochemical markers, their role in the pathophysiology of 





Interactions between the stromal and vascular components of the placenta and uterus 
do not take place in isolation but rather are subject to a superimposed layer of 
regulation by the maternal immune cells that populate the decidua. A dominant 
maternal-factor model used to explain preeclampsia is dysfunction of normal 
trophoblast immune privilege (Kaufman et al., 2003). Two specific immune cells, 
macrophages, and Natural Killer cells have been particularly investigated for their role 
in trophoblast-decidua interactions.  
 
Macrophages are the second most abundant leukocyte population within the human 
decidua (about 20% of total leukocytes) and are natural candidates for contributing to 
tissue remodeling at the maternal-fetal interface (Erlebacher 2013; Reister et al., 
1999). The observations of differential macrophage distributions between 
pregnancies suffering from placental complications such as preeclampsia and fetal 
growth restriction hint at interactions between trophoblast and macrophages (Hunt, 
1990).  
 
Few studies that examined third-trimester histological specimen have reported 
positive findings (Reister et al., 1999; Lockwood et al., 2006; Huang et al., 2008; 
Schonkeren et al., 2011) but others failed to detect significant differences (Reiger et 
al., 2009; Redline et al., 2001; Kim et al., 2007). Therefore, further insight into the role 
of macrophages in decidual arteriole remodelling and placental insufficiency is 










Natural Killer cells are the major maternal immune cell component of the decidua, 
comprising approximately 70% of the Leukocyte population. They are first seen in the 
secretory endometrium prior to implantation and are locally induced by chemokines, 
cytokines, and angiogenic factors to differentiate into cells with highly specialized 
pregnancy-specific functions (Koopman et al., 2003; Manaster et al., 2010, Wallace 
et al., 2012).  Studies have identified as potential roles of NK cells the facilitation of 
vascular changes necessary for maximizing maternal blood flow through the placenta 
(Hanna et al., 2006) and there is strong evidence for their involvement in the aetiology 
of pre-eclampsia and placental insufficiency (Hiby et al., 2004; Hiby et al., 2012). 
Research in first trimester decidual specimens of pregnancies with high-resistance 
uterine artery Dopplers identified reduced NK cell apoptosis when compared with 
normal uterine resistance pregnancies (Fraser et al., 2012).  
 
Hypoxia and oxidative stress 
 
Studies in the early stages of placental development indicate that the fetoplacental 
unit exists under a low oxygen tension environment which increases at the point of 
connection of the intervillous space with the maternal circulation. The result is a 
“physiological” ischaemic-reperfusion injury which has been documented in various 
studies (Jauniaux et al., 2000).   In cases of defective conversion of the maternal 
spiral arteries to low resistance vessels the increasing pressures of the arterial system 
cannot be accommodated and hence areas of the placenta are susceptible to similar 
hypoxia, reperfusion injury and oxidative stress above the physiological levels. A 
variety of studies have found evidence of oxidative stress and hypoxic reperfusion 
injury in cases of preeclampsia and growth restriction and also associated this with 
subsequent increased levels of apoptosis (Heazell et al., 2008; Hung et al., 2006). 
More promising findings were seen in a study  that found Increased levels of 









suggesting that the finding is not a mere consequence of late placental hypoperfusion 




Apoptosis has traditionally been described as programmed cell death and is a part of 
the normal regeneration process of the body. As a process, it possesses 
characteristics that facilitate its purpose, for example, the ability of effective removal 
of apoptotic cells without eliciting an inflammatory response via the action of 
phagocytes. Its role in physiological and pathological placentation has been 
extensively investigated however its precise role in the development of placental 
pathology and clinical conditions such as pre-eclampsia and FGR is yet to be 
determined (Heazell et al., 2008). The reason for this is the inherent methodological 
difficulties in the histological investigation of samples from abnormal pregnancies that 
only become available after delivery (Heazell et al., 2008; Fraser et al., 2012). 
 
Many studies have identified increased apoptotic markers in cases of preeclampsia 
and growth restriction hypothesizing that a tightly regulated process is necessary for 
maintaining the integrity of villous trophoblast (Levy & Nelson 2000, Leung et al., 
2001; Endo et al., 2005; Athapathy et al., 2003). Most of the hypothesized causative 
theories of placental insufficiency described above have been shown to be associated 
with increased apoptosis such as hypoxia and hypoxia re-oxygenation injury which 
has been shown to induce apoptosis in cultured villous trophoblast (Hung et al., Levy 
et al., 2000). Also, links have been identified with decreased immune tolerance 
(Abumare et al., 2006; Sargent et al., 2003) or angiogenic / anti-angiogenic 
interactions (Cockell et al., 1997; Nevo et al., 2006; Levine et al., 2006; Guller et al., 
2007). However, the question still remains as to whether the changes that are being 
measured are secondary to an already damaged placental and not the cause of the 










Newer studies have started to look at the apoptotic process within the context of 
implantation in early pregnancy.  Here apoptosis has been described as a prerequisite 
in the ability of the trophoblast to invade spiral arterioles and promote vascular 
remodelling. Various apoptotic markers have been identified in the decidua even prior 
to the presence of trophoblast in spiral vessels (Smith et al., 2009). In a novel new 
study also described above, evidence showed a possible reduction in apoptosis 
mediated by NK cells in cases which were characterized as high risk for placental 
insufficiency via uterine artery Dopplers. Again the value and role of apoptosis in 
placental insufficiency remains to be determined. 
 
Adhesion molecules and trophoblast invasion 
 
The expression of cell adhesion molecules is necessary for trophoblast invasion 
because these molecules enable the trophoblast to adhere to the extracellular matrix, 
form colonies, and target cells in the vessel wall (Kaufmann & Castelluci 1997; Merviel 
et al., 2001). Various cell adhesion molecules such as E-Cadherins or A-Integrins 
have been investigated for playing a role in the pathogenesis of placental 
insufficiency. Some studies report possible alterations to such molecules while others 
report negative data (Zhou et al., 1997; Lyall et al., 2001; Divers et al., 1995). 
 
In summary clinical and basic research data suggest that maladaptation and mal-
invasion of uteroplacental arteries characteristic of growth restriction and pre-
eclampsia can be a result of intrinsic (trophoblast-related) as well as extrinsic 











1.3.3 Pre-eclampsia vs. normotensive growth restriction 
 
The theory about common origins of pre-eclampsia and fetal growth restriction is well 
accepted as various studies have linked the classical signs of inadequate conversion 
of maternal spiral arteries in placentas from both diseases (Kaufman et al., 2003). 
The extent of overlap of these conditions and the characteristics that separate them 
has been subject of many studies. 
 
In placental histopathological studies, growth restriction with or without Preeclampsia 
seems to share common characteristics such as significantly trimmed placenta and 
reduced intervillous space volume (Aviram et al., 2010, Teasdale 1984)). Placentas 
with preeclampsia in the absence of growth restriction resembled those of age-
matched normal controls with similar mean villous diameters, capillary volume 
densities and capillary/villus surface ratios (Burton et al., 1996; Ansari et al., 2003) 
hence supporting the hypothesis that late-onset PE is a maternal and not a placental 
disorder (Mayhew et al., 2004). What unifies and what differentiates these two groups 
is a topic of on-going investigation with prevailing theories strongly implicating 
predisposition to the metabolic syndrome as the culprit for the development of the 
multi-organ endothelial dysfunction seen in preeclampsia.  
 
The links between preeclampsia and cardiovascular risk factors have been well 
documented however there is some evidence that mothers who had growth restricted 
babies also have increased risks of ischaemic heart disease and later life 
hypertension (Smith et al., 2001; Davey et al., 1997; Kramer et al., 1987). Such 
observations raise the possibility that there is an element of shared endothelial 
dysfunction. However in a large observational study of 39.000 pregnancies comparing 
risk factors of women having normotensive growth restriction versus pre-eclamptic 









with a previous history of SGA neonates and independent of previous pre-eclampsia 
and no link with metabolic syndrome (Villar et al., 2006).   
 
What is clinically evident and well documented is the distinct clinical manifestation of 
the two syndromes. Varying degrees of defective placentation resulting in hypoxia 
and ensuing oxidative stress, inflammation and endothelial activation in combination 
with a pre-existing susceptibility secondary to the maternal metabolic syndrome 
(adiposity, insulin resistance, hyperglycaemia, hyperlipidaemia, coagulopathies, and 
maternal inflammatory mediators) disrupts maternal endothelial function until the 
process crosses a clinical threshold and manifests as preeclampsia. The absence of 
maternal metabolic syndrome or other exogenous inflammatory triggers precludes 
the mother from developing appreciable maternal pathology (Ness et al., 2005; Figure 
1.3). 
 
Evidence to support this includes a difference between neutrophil activation, a marker 
of inflammation in pre-eclampsia but not growth restriction (Von Dadelszen et al., 
1999) suggesting a reduced inflammatory state in the later. Also after pre-eclamptic 
pregnancies, metabolic syndrome markers tend to remain elevated, as does 
cardiovascular risk (Smith et al., 2001). In the case of normotensive growth restriction, 
this effect is much less observed. Measured cholesterol, triglycerides, HDL, LDL, 
very-low-density lipoprotein (VLDL), or intermediate-density lipoprotein (IDL), do not 











Figure 1.2 Schematic representation of a possible pathophysiological pathway in PET 
and FGR.  Pre-pregnancy endothelial dysfunction results in hypoxia-driven 
dysregulation via Hypoxia Inducible Factor (HIF). HIF is associated with decreased 
levels of PLGF and increased levels of VEGF and TGF-β. Subsequent incomplete 
conversion of spiral arteries due to the anti-angiogenic unfavourable environment 
results in an exaggerated inflammatory response as measured by raised levels of the 
pro-inflammatory T lymphocyte (Th-1). A divergent pathway is proposed with women 
exhibiting specific metabolic phenotype manifest the clinical syndrome of PET and 
women without risk factors do not cross the threshold and do not exhibit the maternal 
symptoms but the fetus is still subject to the effects of the malfunctioning placenta and 












When examining risk factors for pre-eclampsia versus normotensive growth 
restriction we see the first being much more common in obese women while the later 
shows a weaker association with raised BMI (Bernstein et al., 1997). In the case of 
diabetes mellitus again we see a stronger association with pre-eclampsia and the link 
to SGA is mostly observed if the severity of diabetes has resulted in vasculopathy 
(Bradley et al., 1988). 
 
1.3.4 Genetic predisposition in placental insufficiency 
 
Several epidemiological studies postulate an inherited component in the 
pathogenesis of placental insufficiency (Ghezzi et al., 2003; Smith et al., 2007).  
Women who themselves are small at delivery are at greater risk for having an SGA 
baby, whereas familial aggregation is well established for both PE and growth 
restriction (Hackman et al., 1983; Magnus et al., 1993). In a recent study investigating 
women having SGA babies or having PE in a genetically isolated population in the 
Netherlands it was found that more than three out of four could be traced back to a 
common single ancestor. In addition, it was found that those women that had PE and 
those that had SGA babies were more closely related than expected by chance 
(Berends et al., 2008).  
 
Another recent large epidemiological study showed that mothers born SGA are more 
likely to develop placental complications such as PE, abruption or stillbirth and in the 
case that both parents were born SGA the risk of the mother developing PE was 
increased 3-fold (Wilkstrom et al., 2011). A recent systematic review showed that if a 
father is born SGA then there is a significant association with the delivery of an SGA 













In conclusion, we see that both pre-eclampsia and growth restriction share common 
pathophysiological findings that could point towards a single underlying mechanism 
which is modulated by different factors either genetic or acquired and results in the 
development of the different clinical manifestations. The quest to understand the 
basic pathogenesis, provide meaningful predictions or attempt possible therapeutic 
interventions requires research to move its focus at progressively earlier gestations 
where the signs of the disease can be absent or increasingly difficult to detect. In the 
following sections of the introduction, we examine closely the various techniques that 
have been used to identify women at risk of placental insufficiency either through risk 
stratification, ultrasound of the uterine arteries or analysis of maternal serum markers 
of defective placental function. 
 
1.4 SCREENING FOR SMALL FOR GESTATIONAL AGE IN PREGNANCY 
 
As mentioned previously the ultimate aim of identifying small fetuses in utero is 
because a proportion of them will suffer from growth restriction. Identifying the fetus 
that is likely to suffer from growth restriction antenatally allows the optimization of 
surveillance during pregnancy to ensure appropriate delivery in a manner that 
minimizes the risks of prematurity but at the same time minimizes the risk of 
intrauterine death (Mandruzzato et al., 2008; Miller et al., 2008).  
 
The ideal screening protocol for SGA is an ever changing concept illustrating the 
difficulty involved in this task. Successful prediction is compounded by a variety of 
factors including the lack of defined thresholds for normality versus abnormality, the 
fact that the assessment of growth velocity (serial measurements) may be more 









as maternal ethnicity (Bricker et al., 2008; Altman et al., 1989). If a fetus is identified 
as SGA a set of criteria is used to ascertain the diagnosis of true FGR. Common 
diagnostic criteria for FGR are presented in Table 1.5. 
 
Table 1.5 Commonly used diagnostic criteria of fetal growth restriction 
 
 
 Estimated fetal weight which is small for gestational age or certain 
biometric measurements being small for gestational age (most predictive 
being abdominal circumference). 
 A reduction in growth velocity as demonstrated by a drop in “centiles” of 
the EFW or biometric parameters. 
 Fetal and maternal blood flow abnormalities demonstrated via ultrasound 
doppler: 
o Increased resistance in the umbilical artery Doppler with 
progression to absent or reversed end diastolic flow. 
o Reduced resistance in the middle cerebral artery signifying a brain 
sparing effect of the hypoxic fetus. 
 Reduced amniotic fluid. 
 Reduced fetal movements or fetal biophysical profile. 
 
 
Many times the diagnosis can only reliably be achieved postnatally by a form of a 
body mass index (BMI) known as the Ponderal Index. However, 50% of newborns 
identified as growth restricted by Ponderal Index had a birth weight above the 10th 
centile and 40% of newborns with a birth weight less than the 10th centile had a normal 
Ponderal Index (Weiner et al., 1989). In cases of perinatal fetal death, for the 
purposes of assigning causation, an autopsy can demonstrate an elevated brain-










Traditionally and in most clinical settings screening has been applied in the second 
or third trimester either in an unselected population or with an initial stratification of 
groups into low or high risk based on maternal characteristics applied early in 
pregnancy. Increasingly though, as more evidence emerges that the origin of obstetric 
pathology arises early in the first trimester in combination with the fact that most 
pregnant women engage with antenatal services in the first trimester as part of routine 
screening for chromosomal abnormalities we observe a consistent effort to employ 
screening modalities such as ultrasound or biochemical testing earlier in gestation 
(Zhang et al., 2010; Nicolaides 2011). 
 
When considering population screening it is important to appraise the viability, 
effectiveness, and appropriateness of performing screening for that particular 
condition. A series of prerequisites known as Wilson’s criteria is a commonly accepted 
evaluative method for this task. The criteria applied on screening for SGA in 
pregnancy are summarized in table 1.6. As can be seen four out of seven criteria are 
not met satisfactorily. However there are continuous efforts to improve on all four 
areas mentioned in the table and there are promising preliminary results in the areas 
of diagnosis SGA, managing the disease during pregnancy and applying early 
therapeutic interventions. Screening for SGA should move in parallel with advances 
in the other areas where criteria are partially met because as mentioned previously 
early prediction and the ability to diagnose or effectively treat are intertwined and early 
selection of a high-risk group will concurrently benefit the other areas as well. 
 
In the following paragraphs, a review of the most relevant screening methods and 
their performance in predicting SGA will be performed with a focus on those applied 

















Criteria met  
 The condition should be an important health problem 
 The natural history of the condition should be understood 
 There should be a recognisable latent or early symptomatic stage 
 
 
Criteria not met or there is uncertainty 
 There should be a test for the condition that is easy to perform and interpret 
and it is acceptable, accurate, reliable, sensitive and specific 
 There should be an accepted management for the disease 
 Treatment should be more effective if started early 
 Diagnosis and treatment should be cost-effective 
 
 
1.4.1 Risk stratification based on maternal characteristics 
 
There are widely known predisposing factors for the likelihood of a fetus being SGA 
and the stratification of the pregnant population in terms of their risk of having an SGA 
pregnancy is an effective way of increasing the detection rate and positive predictive 
value of the screening method. The most relevant identified risk factors for SGA 











High maternal age has been consistently associated with the delivery of an SGA 
neonate. An Odds ratio (OR) of 1.28 for a birth weight <5th centile was reported in 
women aged >35 and 1.49 for women aged >40 (Jolly et al., 2000a). In another study, 
the OR of a mother aged >35 delivering a neonate below the 10th centile was 3.1 
(95%CI 1.9-5.4) (Odibo et al., 2006). Young maternal age has not shown an 
association with SGA (Jolly et al., 2000b). According to the latest RCOG guidance 
maternal age >40 years alone would put a woman in the high-risk category with serial 
growth scans recommended. However, there has been recent data to suggest that 
advanced maternal age might not be associated with stillbirth if congenital 
abnormalities are excluded (Stillbirth Collaborative Research Network 2011). 
 
Parity and past obstetric history 
 
Nulliparity confers a risk over having previous pregnancies of non-SGA babies with 
ORs of 1.31-2.1 (Shah et al., 2010, Zhang et al., 2010). Also in a large population 
study nulliparity has been associated with stillbirth which in line is highly associated 
with SGA (Gardosi et al., 2013).  
 
The association with previous SGA pregnancies and subsequent increased risk of 
SGA is well established (OR 3.9) (Wolfe et al., 1987; Ananth et al., 2007). Even 
stronger is the association with SGA and stillbirth which has been demonstrated both 
in the fact that women with as SGA pregnancy have an increased chance of a 
subsequent stillbirth (Surkan et al., 2004, kleijer et al., 2005) but also women with an 
initial stillbirth have increased risk of a subsequent SGA pregnancy (OR 6.4)(Bakewell 
et al., 1997). More so this association shows a graded response i.e. the earlier SGA 









pregnancy with SGA pregnancies below 33 weeks conferring a 6-13 fold increased 
risk (Rasmussen et al., 2009). 
 
Previous preeclampsia increases the risk of subsequent SGA. In a population cohort 
of 350.000 pregnancies, severe preeclampsia requiring preterm delivery (<37wks) 
had a much higher subsequent risk for SGA (aOR 11.22 (95%CI 7.4-16.9) and term 
preeclampsia having a much smaller association (aOR 1.53 (95%CI 1.24-1.87) 
(Wikström et al., 2011).    
 
In a recent meta-analysis, interpregnancy interval of fewer than 6 months was shown 
to increase the risk of subsequent SGA (aOR 1.26 (95%CI 1.18–1.33) but also a >60 
month interval showed similar risk (aOR 1.29 (95%CI 1.20-1.39) (Conde-Agudelo et 
al., 2006). 
 
Maternal weight, height, and BMI 
 
Maternal pre-pregnancy weight and height are shown to affect the birth weight of the 
neonate in a variety of studies (Kramer et al., 1987; Niswander et al., 1974). The 
extent that this effect can be described as “physiological” or “pathological” is rather 
controversial and stills a subject of scientific debate. In the case of using centiles with 
customization for maternal characteristics, we see an increased association with 
stillbirths and perinatal morbidity/mortality. However studies have attributed this effect 
not directly to the correction for these characteristics but to the inclusion of fetal rather 
than neonatal growth curves (Zhang et al., 2007; Hutcheon et al., 2008). In fact, 
studies examining maternal weight and stillbirth have shown a direct independent 
association and hence supporting the notion that reduced maternal weight can have 
a pathological component (Zhang et al., 2010). In another large screening study of 
70.000 pregnancies, adjustment for maternal characteristics did not improve 









customized centiles in its latest guidance for screening for SGA but recognizes as a 
minor risk factor maternal BMI < 10th centile, BMI 25-29.9th centile and BMI >30th 
centile (OR 1.2(95%CI 1.1-1.3), RR1.2(95%CI 1.2-1.3), RR1.5(95%CI 1.3-1.7).  
 
A slightly less pertinent fact but one shown in several studies is the association 
between the mother being born SGA and the delivery of an SGA neonate. Odds ratios 





Mostly paternal height and less so weight, have been shown to have a small effect 
on neonatal birth weight but since maternal height and weight have a much more 
substantial effect the value of paternal parameters is not widely used (Klebanoff et 
al., 1998; Magnus et al., 2001).  
 
A strong association has been reported between the father being born SGA and 
offspring that are also SGA (Jaquet et al., 2005). In a systematic review of 36 studies, 
the OR was found to be 3.47(95%CI 1.17-10.27) (Shah et al., 2010). The integration 
of this parameter in routine screening is difficult due to the fact that most parents 
might not recall accurately whether born SGA or not.  
 
Also in line with the previous discussed theories of an element of genetic 
predisposition in the origins of placental disease, changing partners alters the risk of 
subsequent SGA so that if a woman had a non-SGA pregnancy and subsequently 
changes partner the risk of SGA increases (aOR 1.19(95%CI 1.1-1.3)(Krulewitch et 















Maternal Chronic hypertension increased the likelihood of an SGA neonate in a 
variety of studies by about 20%. McCowan et al., reports an OR of 2.9 (95%CI 1.6-
5.0) and Allen et al., in a population study of 130.000 pregnancies showed an OR of 
2.5 (95%CI 2.1-2.9) (McCowan et al., 1996; Allen et al., 2004; Zetterstorm et al., 2006; 




The risk of SGA is confined to those diabetic mothers that exhibit signs of 
microvascular disease (Langer et al., 1989; Hare et al., 1977). In a study comparing 
pregnancy outcomes in Type 1 diabetic mothers with microvascular disease 
(retinopathy, nephropathy, hypertension) Infants were more likely to be SGA (OR 6.0; 
95%CI 1.54–23.33) and less likely to be macrosomic (OR 0.46; 95%CI 0.224–0.928) 




The prevalence of anticardiolipin antibodies in a low-risk obstetric population has 
been reported to be between 2.7% and 7% and besides the well-established 
association with fetal loss an association between anticardiolipin antibodies and low 
birth weight has also been reported (Lockwood  et al., 1989; Lynch 1994; Empson et 
al., 2005). Another study also showed a considerable association (RR: 6.22 (95%CI 
2.43–16.0)). Small studies have also shown an association with SLE and SGA which 
seems to be dependent on the severity of the disease (Clowse et al., 2005; Yasmeen 










Other maternal diseases have been associated with the delivery of SGA neonates. 
However their prevalence in the general pregnant population is small or their effect is 
very severity-dependent (i.e. only the very severe form, or uncontrolled disease) and 
hence their predictive value in screening for SGA in a low-risk population is limited. 
Among those are maternal renal disease, severe uncontrolled asthma, uncontrolled 
hyperthyroidism, cyanotic heart disease or cardiac failure. 
 
Method of conception 
 
Consistent evidence shows an association between artificial reproductive techniques 
(ART) and SGA (koudstaal et al., 2000). Two meta-analysis studies have found 
increased ORs of 1.6(95%CI 1.3-2.0) and RR 1.45 (95%CI 1.04-2.00) in singleton 




Smoking has a significant dose-dependent association with SGA,( Meyer et al., 1972) 
with women smoking up to 10 cigarettes daily showing ORs of 1.54(1.39-1.7) and 
those above 10, 2.21(2.03-2.4)(Kramer et al., 1999). In another recent study the 
prevalence of smokers in the first trimester of pregnancy was 10% and again an 
association was found with SGA (1.76 (95%CI 1.03- 3.02). In the same study mothers 
that had stopped smoking before pregnancy were not found at significantly higher risk 
(OR 1.06(95%CI 0.67-1.68) hence indicating that smoking cessation is a beneficial 
intervention (McCowan et al., 2009). 
 
Similar dose dependent effects have been shown with alcohol consumption (Jaddoe 









OR = 1.62 (95% CI 1.26 - 2.09) 3-5 units a day, OR = 1.96 (95% CI 1.16-3.31) (Mills 
et al., 1984).    
 
Other exposures in pregnancy such as cocaine use or low fruit intake pre-pregnancy 
have been shown to be associated with SGA but their use in routine screening would 
be limited as not many mothers would disclose readily cocaine use and diet habits 





Similar to maternal height and weight, ethnicity falls into the physiological vs 
pathological debate. Birthweight varies with ethnicity and non-caucasian women tend 
to exhibit lower average birth weight. The effect obviously is dependent on the 
population examined in mind. At the same time in the UK ethnic minorities appear to 
be at the highest risk of adverse pregnancy outcome including preeclampsia and 
having an SGA neonate as well as stillbirth (Akolekar et al., 2011; Poon et al., 2012, 
Gardosi et al., 2013). First generation African and Pakistani women have the highest 
risk with RR 2.3 (95%CI 1.5-3.6) and 2.1 (95%CI 1.5-3.1) respectively (Gardosi et al., 
2013). This evidence together with evidence showing that adjustment for ethnicity 
does not improve prediction of stillbirth support the argument that ethnicity should not 
















The most basic forms of screening using clinical examination during pregnancy as a 
surrogate for fetal size and the ones that have been traditionally used throughout 
obstetric practice are subjective abdominal palpation and the measurement of the 
symphysio-fundal height (SFH). The first has been consistently shown to be very 
inaccurate predictor with sensitivities of as low as 19% in low-risk populations and 
around 37–50% in high risk populations and is no longer recommended in routine 
practise (Bais et al., 2004; Kean & liu 1996; RCOG Green-top guideline No. 31). 
 
SFH measurement with the recommended standardized technique is believed to have 
a value in screening for SGA but with a great variation in predictive accuracy with 
significant Intra– and inter–observer variation and very prone to confounding factors 
such as maternal obesity, fetal lie, the presence of fibroids or polyhydramnios.   
 
A large study reported a sensitivity of 27% and specificity of 88% (Bailey et al., 1989; 
Persson et al., 1986) with serial measurements improving slightly the accuracy.  
Nonetheless, the minimal cost involved and the opportunity to perform this test in 
routine antenatal visits makes it an appropriate adjunct to more accurate detection 
methods. In a Cochrane systematic review, no impact in perinatal outcome was 
detected with the use of SFH (Neilson 2000). 
 
First-trimester crown-rump length 
 
In a study comparing first trimester expected crown-rump length (CRL) based on 
maternal menstrual data and actual CRL, an association was found between small 









2010). Similar results were found in a study examining pregnancies resulting from 
assisted reproduction techniques (ART) were the conception date is known showing 
that evidence of impaired growth can be detected from the first trimester of pregnancy 
(Bukowski et al., 2007). However, this observation is difficult to incorporate into 
routine screening since dating the pregnancies by fetal CRL in the first trimester is 
standard clinical practice and hence the effect is artificially normalized.   
 
Second or third-trimester biometry 
 
The two prevailing techniques of assessing fetal size via ultrasound in the second 
and third trimesters are estimated fetal weight (EFW) and Abdominal circumference 
(AC). A measurement of either EFW or AC below the 10th centile for gestation 
produced sensitivities in the range of around 10% for the detection of an SGA neonate 
in a low-risk population and between 50-90% in a high-risk population (Chauhan et 
al., 2006; Chang et al., 1992). In a Cochrane meta-analysis of eight trials comparing 
routine ultrasound screening after 24 weeks with no screening found no overall 
evidence that routine screening in a low-risk population improved detection of an SGA 
neonate (RR 0.98% CI 0.74-1.28) or improved perinatal mortality (RR 0.94% CI 0.55-
1.61) (Bricker et al., 2008).  
 
A reduction in growth velocity has also been proposed as a discriminating factor 
between FGR and constitutional SGA (Larsen et al., 1990, Royston et al., 1995). A 
study examining change in AC or EFW growth velocity in a high-risk population 
showed better correlation compared with single AC or EFW measurements and 
adverse perinatal outcome (Chang et al., 1993). 
 
The RCOG currently recommends ultrasound biometric screening with serial 
ultrasound measurements of customized EFW or AC from 26-28 weeks only in high-










1.4.3 Uterine artery Doppler as a screening tool for small for gestational age 
 
Doppler ultrasound of the uterine arteries (UAD) has the ability to evaluate the 
uteroplacental circulation in a non-invasive way. The technique has shown increasing 
use in screening for PE with good predictive values in severe disease (Poon et al., 
2009). Given the common pathophysiological findings of PE and FGR, its use has 
extended to the evaluation of uterine artery resistance in placental insufficiency in the 
absence of PE. 
 
The technique of evaluating the uterine vessels involves insonation of the lateral walls 
of the cervix and uterus either through the transvaginal route or the transabdominal 
route. Visualization of the vessels is aided by the use of colour flow mapping and 
sampling the blood flow via pulsed Doppler (Jurkovic et al., 1991). The resistance can 
be calculated by using a variety of indexes. The most commonly used indices are the 
pulsatility and resistant index (PI and RI) which showed the highest predictive value 
(Cnossen et al., 2008, Gomez et al., 2008). The technique has been standardized in 
the screening of PE (Poon et al., 2009) and can be performed both in the second or 
the first trimester. Screening performance in the setting of PE has been shown to be 
optimal with the use of the lowest uterine artery PI (UAPI) (Poon et al., 2009; 
Napolitano et al., 2010). UAPI shows a progressive decrease from the first trimester 
until the late stages of pregnancy (Gomez et al., 2008). Notching of the uterine 
arteries is considered a sign of increased resistance however its value as a predictive 
marker in the first trimester has been shown to be poor, especially due to high false 











Pulsatility index =(peak systolic velocity - minimum diastolic velocity)/Mean 
velocity 
  




Second trimester screening 
 
A multitude of studies has shown a degree of association of high uterine blood flow 
resistance with the delivery of an SGA neonate. There is a lot of heterogeneity in the 
use of resistance indices and definitions of SGA. In general, the prediction is stronger 
in severe/preterm SGA and when screening is limited in high-risk populations. Data 
from a systematic review summarizing all studies in the literature showed very 
heterogeneous results. In a low risk setting sensitivities ranged between 12-53% 
while specificities for all SGA ranged between 83-95% and for severe SGA 26-65% 
and 88-91%. When only a high-risk population was screened prediction was improved 
with ranges from 29-89% and 68-92% and for severe SGA 64-82% and 80-92% 
(Cnossen et al., 2008). Current RCOG guidelines advise against universal UAD 
screening in the second trimester but support UAD use in high-risk patients (RCOG 




Studies have demonstrated that uterine artery Doppler indices reflect the degree of 
trophoblastic invasion in the first trimester (Prefumo et al., 2004). The observation 
that trophoblast invasion was maximal in the first trimester justifies the evaluation of 









2000). Studies that have assessed the value of uterine Doppler in the prediction of 
SGA in the first trimester of pregnancy are summarized in Table 1.7. 
 
Table 1.7 Studies examining first-trimester uterine resistance in prediction of SGA in 
low-risk populations 





Melchiorre et al., 
2009 
377 2445 RI>95th 16.7% 4.9% <10th 
Poon et al., 2008 296 609 MoMs 17.6% 10% 
<5th 
customized 




Dugoff et al., 2005 12 1008 RI>0.82 16% 5% <10th 
Gomez et al., 2005 37 999 RI>95th 24% 4.9% <5th 
Martin et al., 2001 290 3045 mPI>2.35 11.7% 4.4% <10th 
Severe SGA (<32 wks) 
Martin et al., 2001 181 3045 PI>2.35 27.8% 5.0% <10th 
 
 
Few studies exist in the literature but they seem to have relatively homogeneous 
definitions of SGA being either the 5th or 10th centile. At the same time, all studies 
have used either RI or PI as a measure of resistance. Comparable results can be 
seen across all studies with sensitivities ranging between 12-24% for false positive 
rates between 5 -10%. All the studies have examined low-risk obstetric populations. 
Martin et al. stratified further SGA by severity (<32wks) and showed improved 
prediction in the high-risk group. 
 
The value of uterine artery Doppler as a screening tool in isolation is low. However, it 









placentation and its value in combination with other predictive parameters is to be 
determined.  
 
1.4.4 Mean arterial pressure 
 
Chronic hypertension in pregnancy is a recognized risk factor for the delivery of an 
SGA neonate. Measurement of blood pressure at the booking visit is routine practice 
in most established antenatal surveillance protocols. At the same time, many studies 
have examined the use of blood pressure (BP) measurement as a screening test for 
the subsequent development of hypertensive disorders in pregnancy and have been 
analysed in a recent systematic review (Cnossen et al., 2008). Evidence shows that 
women destined to develop PE can exhibit higher blood pressure readings as early 
as in the first-trimester of pregnancy (Moutquin et al., 1985; Higgins et al., 1997). By 
definition when examining pregnancies that resulted in the delivery of SGA neonates 
in the absence of hypertensive disorders of pregnancy we exclude those that 
subsequently developed hypertension. However, the use of BP screening in a 
systematic way with the use of Mean Arterial Pressure (MAP) readings has been 
successfully incorporated in routine screening for PE in the first trimester of 
pregnancy in some tertiary centers (Poon et al., 2011). No study so far has examined 
the value of MAP in screening for SGA but the incorporation of this measurement into 
a predictive algorithm for SGA in the first trimester might have a value through 
detecting either cases of previously undiagnosed chronic hypertension or cases that 











1.4.5 Nuchal translucency 
 
Few studies have raised the possibility for an association between fetal nuchal 
translucency thickness (NT) and birth weight; however, the available published data 
regarding this possible association is limited (Kelecki et al., 2005). A negative 
correlation was found with Δ-NT and the delivery of SGA neonate in a recent study 
with aOR of 0.57(95%CI 0.38-0.86) (Papastefanou et al., 2012). The proposed 
mechanism for the association of Δ-NT with fetal growth in a small population of 
diabetic pregnancies was that hyperglycemia, which is a causal factor for large for 
dates neonates causes augmented capillary permeability, resulting in increased 
collection of nuchal fluid. Given the availability of data collected from routine first 
trimester screening the presumed association warrants further investigation. 
 
1.4.6 Biochemical markers in screening for small for gestational age  
 
A variety of biochemical markers detected in maternal blood has been evaluated in 
the prediction of an SGA neonate (Table 1.8). The majority of these markers have 
been seen in parallel with research on PE and others are already in use in screening 
for aneuploidies. Many have been extensively evaluated in the second and third 
trimesters and less so in the first trimester. By the nature of placental insufficiency in 
the vast majority of times as disease progresses the biochemical response gets 
accentuated. Hence many studies have demonstrated marked differences between 
biomarkers in the third trimester. However since the focus of research effort has 
moved towards the assessment of placental insufficiency in the first trimester, the 
following review of the relevant biomarkers will focus on those markers that have 












Table 1.8 Biomarkers for predicting small for gestational age identified in the literature 
(Conde-Agudelo et al: Novel biomarkers for predicting intrauterine growth restriction: 





Placental growth factor 
Soluble fms-like tyrosine kinase-1 
Soluble endoglin 









Soluble vascular cell adhesion 
molecule-1 








Interleukin-1 receptor antagonist 
Interleukin-12 
Eotaxin 









Insulin-like growth factor binding 
protein-1 and -3 
A disintegrin and metalloprotease-12 
Placental protein-13 
Activin A 
Placental growth hormone 
Pregnancy-specific b-1-glycoprotein 
Annexin A5 
Hepatocyte growth factor 
 
Others 
Urinary albumin:creatinine ratio 
Vitamin D 
Thyroid function tests (thyroid-
stimulating hormone, free 




















Placenta proteins / Hormones 
 
Pregnancy Associated plasma protein A (PAPP-A) 
 
PAPP-A is a protease that facilitates the release of free insulin-like growth factor (IGF) 
(Lawrence et al., 1999). IGFs are believed to play an important role in the regulation 
of trophoblast invasion. Low PAPP-A is presumed to be a reflection of reduced IGFs 
and has been associated with poor placental growth and placental-related conditions 
(van Kleffens et al., 1998; Irwin et al., 1999; Conover et al., 2004). Associations have 
been found with low PAPP-A and spontaneous fetal loss, stillbirth, severe pregnancy-
induced hypertension (PIH), preeclampsia, and SGA infant. In a systematic review of 
screening studies performed in the first trimester combined predictive value for SGA 
<5th centile was a level of PAPP-A < 1st centile with positive LR of 4.36(95%CI 3.27-
5.80) and negative LR 0.97(95%CI 0.96-0.98). In a large screening study with 33000 
controls and 1300 SGA pregnancies, the sensitivity of screening with low PAPP-A 
was 12.2% for an FPR of 9.5% (Dugoff et al., 2004). In conclusion, the value of PAPP-
A in isolation for predicting SGA is low but this marker might have a value in combined 
screening. RCOG guidance considers a PAPP-A level of <0.415 MoM (5th centile) at 
first trimester screening a major risk factor (OR 2.7)  and recommends further 
monitoring with growth scans in the 3rd trimester. Studies examining the value of 















Table 1.9 Studies examining PAPP-A in the first trimester 
 
Beta Chorionic Gonadotrophin 
 
β-hCG in addition to its function in the regulation of steroidogenesis during early 
gestation promotes trophoblast cell motility (Zygmut et al., 1998). β-hCG /LH 
receptors are abundantly expressed in uterine endothelial cells implicating a possible 
functional responsiveness of these cells to β-hCG and a possible role of β-hCG as an 
angiogenic factor (Lei et al., 1992; Toth et al., 1994). Some studies have associated 














2004 Krantz 270 6276 
<5th centile 
MoM 
  <10th 
DR 9.7% 
FP 4.9% 




































hCG has shown small predictive value with a meta-analysis of 5 studies performed in 
the first trimester showing a β-hCG > 2MoM having a positive LR 1.74(1.48-2.04) and 
negative LR 0.95(0.93-0.96) (Morris et al., 2008). β-hCG is widely performed as part 
of screening for aneuploidies and might have a value as part of a combined screening 
protocol. 
 
Placental protein 13 (PP13) 
 
Placental protein 13 (PP13) is a 32-kd dimer protein and is a placental product thought 
to have a role in implantation and maternal spiral artery remodelling (Sammar et al., 
2005; Burger et al., 2004). Levels measured in the first trimester have been found to 
be reduced in women with early preeclampsia (Nicolaides et al., 2006). Two studies 
have examined the value of PP13 in the first trimester in women delivering SGA 
neonates and are summarized in table 1.10. In a study comparing 42 SGA 
pregnancies with 290 controls for a FPR of 10% the sensitivity for PP13 was 33% and 
OR 4.3 4.3 (95% CI, 2.1-9.1) (Chafez et al., 2007). In another study, no significant 
difference was found between SGA and controls and the authors in similar 
populations and with similarly defined SGA group (<5th) (Cowans et al., 2008). The 
value of PP13 in the first trimester in the prediction of SGA remains to be confirmed.  
 















2008 Cowans 488 364 1.058MoM 1.096MoM ns <5th  











A-Disintegrin and Metalloprotease-12 (ADAM12) 
 
A-disintegrin and metalloprotease (ADAM12) is a placenta-derived glycoprotein that 
has been shown to have regulating properties upon the bioavailability of insulin-like 
growth factor which in turn promotes placental growth (Shi et al., 2000).  ADAM-12 
has been shown to be decreased in the first trimester in both PE and SGA 
pregnancies (Spencer et al., 2008; Cowans et al., 2007). Studies examining ADAM12 
as a first-trimester marker of SGA are summarized in table 1.11. A study examining 
296 SGA pregnancies detected a significant difference in the levels of ADMA12 in the 
first trimester (SGA 0.84 vs Control 1.01 p<0.001) (Poon et al., 2008) but when used 
in a multivariate predictive model did not confer additional value in the screening 
performance. Its value in a larger population sample will be examined in further 
chapters of this thesis.    
 
 




year Authors n SGA n controls Lev SGA Lev contr. P  value Def SGA 
2010 Matwejew 8 452 0.92 MoM 1.03 MoM ns <10th 
2008 Poon 296 570 0.848 MoM 1.011 MoM P<0.001 <5th Gardosi 
2007 Cowans 523 414 0.885 MoM 1.0 MoM P<0.00001 <5th 












An imbalance between angiogenic and anti-angiogenic factors has been implicated 
as a mechanism of disease in PE and for delivery of a small-for-gestational-age 
neonate (Shibata et al., 2005; Tidwell et al., 2001).  
 
Placental Growth factor 
 
Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth 
factor) subfamily and is believed to be a key molecule in angiogenesis of the placental 
trophoblast (Luttun et al., 2002). Low levels of PLGF have been associated with PE 
but also low maternal serum concentration of PLGF has been reported in pregnancies 
complicated by the birth of SGA neonates in the absence of PE. Studies that have 
investigated the levels of PLGF between normal pregnancies and those delivering 
SGA neonates in the first trimester are summarized in table 1.12. The largest study 
examining PLGF in the first trimester for the prediction of SGA compared 296 
neonates born with a BW <5th centile with 609 controls found that PLGF was reduced 
in the SGA group and the use of this marker in isolation had a sensitivity of 14.5% for 




















Table 1.12 Studies examining PLGF in the first trimester 
 
Soluble fms-like tyrosine kinase 1 (sFlt1) and Soluble Endoglin 
 
Soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sENG) are both anti-
angiogenic factors. It has been hypothesized that increased levels might be reflective 
of the endothelial dysfunction seen in impaired placentation. Several studies have 
reported that in PE the maternal plasma concentration of sFLT1 and sEng is 
increased (Stepan et al., 2007; Masuyama et al., 2007; Foidart et al., 2010). Few 
studies have shown increased levels of these angiogenic factors in the second or 
third trimester in cases of SGA without PE and are summarized in table 1.13. There 













2010 Cowans 8 452 0.56MoM 0.99MoM P<00.1 <10th  











2008 Erez O 145 201 30pg/ml 34.5pg/ml P=0.005 <10th  
2008 Romero. 56 46 No value No value P<0.0009 <10th  















SGA. In one study a very small difference was demonstrated for sFLT1 but not sENG 
(Erez et al., 2008). Also in a recent study, no difference in first trimester levels of 
sFLT1 was detected between cases of PE and controls (Akolekar et al., 2010). In the 
following chapters of this thesis, we will examine the levels of sENG in SGA 
pregnancies in the first trimester. 
 
 









Lev SGA Lev contr. P  value Def SGA 
First Trimester 
2008 Erez O 145 201 7.1ng/ml 7.2ng/ml  <10th Gest 
2008 Romero. 56 46 No value No value P<0.0001 <10th Gest 
Second or third trimester 












15 40 7.5ng/ml 6.5ng/ml P<0.05 
23w 
gest 
SGA <5th for 
Gest and Sex 









Table 1.14 Studies examining sFLT-1 in the first trimester 
 
 
Thyroid stimulating Hormone, Free Triiodothyronine, and Free Thyroxine 
 
In-vitro studies reported that thyroid hormone receptors are expressed in extravillous 
human trophoblast and thyroid hormones upregulate proliferation and the invasive 
potential of this trophoblast (Barber et al., 2005; Oki et al., 2004). The addition of 
thyroid hormones to an organ culture system of human placental tissue from early 
pregnancy stimulated the production of several placental hormones, including 
progesterone, human chorionic Gonadotrophin, and estradiol (Maruo et al., 1991). 
There is also contradictory evidence that clinical and subclinical hypothyroidism is 
associated with increased risk for both PE and birth of SGA neonates in the absence 
of PE (Leung et al., 1993; Levine et al., 2009; Sahu et al., 2010, Blazer et al., 2003; 
Casey et al., 2007; Allan et al., 2000). In a recent study it has been reported that in 
pregnancies that develop PE, maternal serum thyroid stimulating hormone (TSH) at 






Lev SGA Lev contr. P  value Def SGA 
First Trimester 
2008 Erez O 145 201 1615pg/ml 1788pg/ml P=0.005 <10th for Gest 




13 16 2912pg/ml 2472pg/ml P=0.99 
<10th sex gender 
gest 




13 38 879.3pg/ml 451pg/ml P<0.05 
<5th ?customized 




16 15 4479pg/ml 2199pg/ml P<0.0086 <10th gest 
2008 Erez O 145 201 1799pg/ml 1687pg/ml P=0.005 <10th for Gest 









normotensive controls (Ashoor et al., 2010). A summary of the studies that has 
investigated the association of thyroid hormones with birthweight is presented in table 
1.15.  The prevalence of maternal thyroid hypofunction at 11-13 weeks’ of gestation 































































































0.6%   0.7% 0.83 
BW<250
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1.4.7 Combined screening protocols 
 
The endpoint of antenatal screening is the reduction in stillbirths secondary to FGR 
along with a reduction in perinatal morbidity. In isolation screening by maternal risk 
factors, Doppler ultrasonography, or maternal serum analytes has not proven 
sufficient in the prediction of adverse pregnancy outcomes to permit routine clinical 
use, many investigators have attempted to improve the predictive value by combining 
these modalities (Imdad et al., 2011; Zhang et al., 2010, McCowan et al., 2010). The 
combination of uterine artery Doppler and maternal serum markers has been shown 
in case-control and cohort studies to have an improved predictive ability for the SGA 
neonate, although predictive values are still poor (Filipi et al., 2011; Stampalija et al., 
2010).  Use of combination testing in the 2nd trimester appears to predict adverse 
outcome related to placental insufficiency more effectively than 1st trimester 
screening (Dane et al., 2010). 
 
Current Royal College of Obstetricians and Gynaecologists guidance on screening 
for SGA in pregnancy recommends that all women should be assessed at booking 
for risk factors for an SGA fetus. Those with a major risk factor should be referred for 
serial ultrasound growth measurements and Dopplers from 26-28 weeks of gestation 
while those with three or more minor risk factors should be referred for uterine artery 
Doppler at 20-24 weeks of gestation with a view to being stratified into the high-risk 
category depending on the uterine Doppler results. The risk factor and diagram of 

























There is no published data on the performance of this screening strategy. What is 
apparent, however, is the need for an improvement in detection of placental disease. 
Increasing evidence illustrates the strong link between SGA and stillbirths and 
according to National Statistics, the stillbirth rates in the United Kingdom are among 
the highest in high-income countries with little improvement since the 90s (Office of 
National Statistics 2011; Flenady et al., 2011). In a recent study across 19 maternity 
units in the UK in a 2-year period, it was found that the overall detection rate of SGA 
neonates (BW<10th centile) was only 31%. This is within a setting of nationally 
coordinated maternity care provision with uniform guidelines. Furthermore, when 
examined a cohort of 195 stillbirths within the studied population which were thought 
to be secondary to FGR only 17.9% of them were detected antenatally (Gardosi et 
al., 2013). In an earlier confidential inquiry into stillbirths in 2007 only 21% of cases 
that were thought to be due to FGR were detected antenatally (Confidential inquiry 
into stillbirths with FGR 2007, Perinatal institute). 
 
Screening in the first trimester 
 
Early detection of a high-risk group has multiple aims. Firstly, it allows targeted 
maternal and fetal surveillance with the more focused allocation of resources. Early 
recognition of SGA could improve maternal and perinatal outcome by administration 
of medication for fetal lung maturation and early delivery (Alfirevic et al., 1995; 
Figueras et al., 2010). Secondly, it allows the possibility of preventative interventions 
at a time that they are more likely to have a therapeutic effect (i.e. the time of 
trophoblast invasion). Low-dose aspirin is an example of a preventative intervention 
that could be targeted to those with evidence of abnormal placentation (Askie 2007). 
Not many studies have applied a combined protocol for the prediction of SGA in the 
absence of PE. The available studies in the literature are summarized in table 1.16. 









the use of maternal risk factors, PLGF and PAPP-A in the first trimester detected 
36.8% for a FPR of 10%.  
 
Table 1.16 First trimester combined screening studies 
 
 
1.5 THERAPEUTIC AND PREVENTIVE INTERVENTIONS 
Although multiple therapeutic strategies have been tested to promote intrauterine 
growth and decrease perinatal morbidity and mortality limited, if any, success has 
been achieved in this area.  In the developed world the single most successful 
intervention for the reduction of FGR secondary to placental insufficiency is smoking 
cessation (Lumley et al., 2009).  In developing countries, balanced nutritional 
supplements in undernourished women and magnesium and folate supplementation 
(in some studies) decrease the rate of SGA newborns (Glumezoglu et al., 2003). 
Aspirin administration for the prevention of defective placentation has shown 
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1.5.1 Timing of delivery and steroid administration 
 
The two principle therapeutic interventions in SGA pregnancies are the administration 
of prenatal steroids and delivery. The administration of a completed course of steroids 
is recommended until 34 weeks’ gestation and shows the strongest therapeutic effect 
in cases of preterm iatrogenic delivery (RR 0.77(0.67-0.89) (Baschat et al., 2005; 
Morris et al., 2013). The timing of delivery in early-onset FGR still remains challenging 
because gestational age has an overriding effect on the neonatal outcome until the 
late second trimester and randomized trials of specific delivery triggers are lacking 
(Baschat 2011). Despite the uncertainties in the optimum management of the SGA 
fetus when considering the benefits of screening as a whole data support that early 
antenatal detection improves outcome. In a study from Sweden awareness of SGA 
before delivery, in combination with a structured program of surveillance for those 
identified as SGA, was found to be related to a four-fold lowered risk of adverse fetal 
outcome (Lindqvist et al., 2005). Also in support of an early risk stratification protocol 
a systematic review of 12 randomized, controlled trials of Doppler ultrasonography of 
the umbilical artery in high-risk pregnancies reported that, in the Doppler group, there 
was a 52% reduction in the number of caesarean section rates for fetal distress (24%-
69%). Furthermore, the clinical action guided by Doppler ultrasonography reduced 




The hypothesis that antiplatelet agents might prevent placental-related complications 
such as PE and FGR holds considerable interest for the last 30 years (Bujold et al., 
2010). Its use is hypothesized to prevent failure of physiological spiral artery 
transformation and thus impaired placentation. In a randomized study of 
periconseptual aspirin administration in ART patients it was found that in the aspirin 









significantly lower compared to the placebo group suggesting that early aspirin 
administration might have a beneficial role in improving early placental blood flow 
(Haapsamo et al., 2008). Increasing data are emerging from meta-analysis of 
randomized controlled trials that the use of early aspirin administration before 16wks 
reduces the rates of PE and SGA (Bujold et al., 2010, Roberge et al., 2012). In a 
recent meta-analysis of 42 studies, low dose aspirin started before 16 weeks’ was 
found to significantly reduce the risk of SGA 0.46(0-33-0.64)(Roberge et al., 2013). 
Given the current emerging evidence the benefits of early detection of pregnancies 
at risk of impaired placentation becomes increasingly relevant.   
 
1.5.3 Smoking cessation 
 
Smoking cessation during pregnancy improves fetal outcomes (Lumley et al., 2009; 
Batech et al., 2013). Early screening besides taking into account this parameter as a 
risk factor for SGA allows the opportunity for mothers to engage earlier with antenatal 
services and perhaps increase the opportunity to implement behavioural interventions 
and support in order to promote smoking cessation. 
 
1.5.4 Nutritional supplements 
 
In a systematic review of trials, micronutrient supplementation showed a modest 
increase in mean birth weight and a reduction in the incidence of SGA neonates (RR 
0.68, 95% CI 0.56–0.84) (Haider et al., 2006). Most of the included studies were done 
in developing countries with high fertility rates, low maternal body mass index (BMI), 
a high prevalence of iron deficiency anaemia and frequent subclinical micronutrient 
deficiencies and this makes it uncertain whether this effect will be replicated in the 
setting of developed countries. Although maternal nutrient supplementation has been 









nutrients), there is not enough evidence to evaluate its effects. (Say et al., 2003, 
RCOG Green Top guideline no.34). 
 
1.6 CONCLUSION 
We have seen that placental insufficiency and the ensuing growth restriction is a 
prevailing problem in modern obstetric care. Despite technological advances in fetal 
monitoring and detection of novel markers of placental function the fundamental aim 
or reducing the number of stillbirths still remains a challenge.  Closer examination of 
the aetiology of stillbirths puts fetal growth restriction as the number one preventable 
causative factor. A higher understanding of the normal and abnormal processes 
underlying placental implantation and the ever increasing realization that the first 
trimester of pregnancy is the window of opportunity for both risk stratifying 
pregnancies or applying novel therapeutic techniques makes the need for an accurate 
and reliable screening system a priority. In the following chapters of this thesis we 
evaluate the most promising current modalities in an attempt to develop a combined 
predictive algorithm for the delivery of an SGA neonate in the first trimester of 

























We hypothesize that it is possible to predict the birth of small for gestational age 
neonates from the first trimester of pregnancy by using a combination of maternal 




 To develop a reference range of birthweight with gestation for an inner city 
multi-ethnic London population. 
 
 To investigate maternal risk factors associated with the delivery of SGA 
neonates and to develop a screening algorithm based on multivariate analysis 
of those maternal risk factors. 
 
 To examine the associations of biophysical markers such as fetal nuchal 
translucency, mean arterial maternal blood pressure and uterine artery 
pulsatility index with the birth of an SGA neonate and to examine their value 
in screening for SGA in the first trimester of pregnancy. 
 
 To examine the association of biochemical markers detected in maternal 
blood in the first trimester of pregnancy with the birth of an SGA neonate and 
evaluate their performance in the prediction of the birth of an SGA neonate. 
 
 To evaluate the combined performance of the above maternal risk factors, 
biophysical and biochemical markers for the prediction of SGA neonates and 
develop a predictive algorithm that can be applied in the first trimester of 
pregnancy.  
 
 To compare the estimated performance of the combined predictive algorithm 
with existing screening strategies for the detection of SGA fetuses antenatally.








CHAPTER 2. PATIENTS AND METHODS 
 
2.1 STUDY POPULATION 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine first hospital visit in pregnancy between 
March 2006 and September 2009. In this visit, which is held at 11+0 to 13 +6 weeks of 
gestation, we record maternal characteristics and medical history and perform 
combined screening for aneuploidies by measurement of the fetal CRL and NT 
thickness and maternal serum PAPP-A and free β-hCG (Robinson & Fleming 1975; 
Snijders et al., 1998; Kagan et al., 2008). We also measured the maternal MAP by 
automated devices (Poon LC et al., 2010) and used transabdominal colour Doppler 
ultrasound to visualise the left and right uterine artery, measure the PI in each vessel 
and calculate the mean PI (Placencia et al., 2007). At the same time, we collected 
samples of serum and plasma which were stored at -80 ° C for subsequent 
biochemical analysis.  
 
During the study period, first-trimester combined screening for aneuploidies was 
carried out in 36,743 singleton pregnancies. We excluded 3,893 cases because they 
had missing outcome data (n = 2,005), the pregnancies resulted in miscarriage, 
termination or the birth of babies with major defects (n =1,136), or they were 
complicated by PE as defined by the International Society for the study of 
Hypertension in Pregnancy (n = 752) (Davey and MacGillivray, 1988). In the 












2.2 ETHICAL COMMITTEE APPROVAL 
 
Written informed consent was obtained from the women agreeing to participate in the 
study, which was approved by King’s College Hospital Ethics Committee (ref: 02-03-
033). An information leaflet was provided to all patients outlining all basic details 
(Table 2.1). 
 
Table 2.1 Patient information leaflet        
   
Patient information leaflet 
 
Early prediction of women at risk of preeclampsia and fetal growth restriction 
 
We would like to invite you to take part in a research study. Before you decide 
whether to do so it is important for you to understand why the research is 
being done and what it will involve. Please take time to read this leaflet. Ask 
us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. Thank you for 
reading this. 
 
What is the purpose of the study? 
 
We are looking for new ways through scientific research to improve the care 
of pregnant women and their unborn babies. As part of this work, we are 
inviting all women that attend for the 11-13 weeks scan to participate in a 
large study on preeclampsia (high blood pressure of pregnancy) and fetal 
growth restriction (poor fetal growth). 
 








Preeclampsia and fetal growth restriction are two important complications of 
pregnancy which can have serious implications for mother and baby. These 
problems can affect any pregnant woman, irrespective of previous healthy 
pregnancies and irrespective of how healthy the mother is. 
 
Our aim is to try and identify the women who are at high risk of developing 
these problems and to do so as early in pregnancy as possible. 
 
Why have I been chosen? 
 
All pregnant women attending for the 11-13 weeks scan are welcome to take 
part in this study. 
 
Do I have to take part? 
 
It is up to you to decide whether you would like to take part. If you decide to 
take part you will be given this information sheet to keep and will be asked to 
sign a consent form. Once you have decided to take part you are still free to 
withdraw at any time without giving any reason. A decision to withdraw at 
any time, or a decision not to take part, will not affect the standard of care 
you receive.   
 
What will happen to me if I take part?  
 
The study consists of three components which are done at the time of the 11-
13 week scan:  
 
1. Maternal blood markers  









This involves us saving some of the blood that we take from you as part of 
the test to determine the risk for Down’s syndrome. Since new tests may 
become available in the future we feel it would be prudent to store some of 
your blood sample for future studies.  
 
 
2. Measurement of blood flow from the mother to the placenta  
 
During your visit, we will use ultrasound to examine your baby. We will also 
use ultrasound to look at the vessels that supply blood to the uterus and the 
placenta. This extra scan takes a couple of minutes to do. It is not 
uncomfortable and does not carry any risks to you or your baby.  
 
3. Blood pressure measurement  
 
During your visit, we will measure your blood pressure. Usually, this 
measurement is taken from your left arm. We are trying to find out if it is 
better to use the reading from the left or the right arm or the average one from 
both arms. We would take blood pressure measurements from both of your 
arms simultaneously.  
 
What are the possible benefits of taking part?  
 
If we find that you have high blood pressure we will arrange for any follow-
up tests and monitoring that would be necessary. This will have a direct 
benefit for you. In addition, the information we get from the study may help 
us to help you and/or other women in the future.  









What are the possible disadvantages and risks of taking part?  
 
The blood pressure measurement may also be uncomfortable because of the 
inflation of the cuffs. If you find this examination intolerable please let us 
know, we will stop immediately.  
 
Will my taking part in this study be kept confidential?  
Yes. All the information about your participation in this study will be kept 
confidential.  
What if I want to complain?  
 
If you have a concern about any aspect of this study, you can ask to speak 
with one of the researchers who will do their best to answer your questions. 
By agreeing to take part in the study you do not lose any legal rights. If you 
remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. Details can be obtained from the hospital 
(Contact: Mr. Tim Hiles on 0207 346 3983). 
  
What will happen to the results of the research study?  
 
It is hoped that the results will be published in medical journals and perhaps 
also in the press. You may request a copy of any published documents in 
relation to the study. You will not be identified in any of these reports.  
Who is organising and funding the research?  
 
This research is carried out by the team of Professor Kypros Nicolaides and 
it is funded by the Fetal Medicine Foundation (which is a registered charity). 
 








              
 
 
Table 2.2 Consent form 
 
Consent form  
 
Research Study: Early identification of preeclampsia and fetal growth 
restriction  
 
We are requesting your permission to participate in the research study that 
essentially involves the following:  
 
1. Maternal blood analysis  
2. Measurement of blood flow to the placenta  
3. Measurement of blood pressure  
 
We hope that you find it worthwhile to take part in this study. If you should 
decide to participate, please sign the consent below. We would ask you to 
sign three copies of this form, one for your own records, one for our research, 
and one for your medical notes. Thank you.  
 
1. I confirm that I have read and understand the information sheet for the 
above study and have had the opportunity to ask questions.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without affecting my medical care or legal rights.  
• I agree / disagree to have a sample of my blood taken for current testing and 
storage for future tests  
 








• I agree / disagree to the measurement of flow in the uterine arteries  
 
• I agree / disagree to the measurement of my blood pressure.  
 
Patient's name:   
ID number:   
Date: .  
Patient's signature: .  
Doctor's name: .  
Doctor's signature:  
 
     
 
 
2.3 RECORDING OF INFORMATION 
 
Women attending for their routine 11-13 weeks scan were asked to supply the 
following information during a medical interview and were documented electronically 
via computer software.  
 
 Age 
 Race (Caucasian, African, South Asian and Mixed),  
 Cigarette smoking during pregnancy, 
 Method of conception (spontaneous or assisted conception by either ovulation 
induction alone or in vitro fertilisation)  
 Medical history (including chronic hypertension, diabetes mellitus, anti-
phospholipid syndrome, thrombophilia and sickle cell disease) 








 Medication (including anti-hypertensive, anti-depressant, anti-epileptic, 
aspirin, steroids, betamimetics, insulin and thyroxine), parity (parous, 
nulliparous with no previous pregnancies, nulliparous with miscarriage or 
termination before 24 weeks) 
 Previous pregnancy with PE (yes or no) and family history of PE (mother, 
sister or both).  
 Previous delivery of an SGA neonate (only SGA, only non-SGA or both SGA 
and non-SGA) 
  
The maternal characteristics of each of the outcome groups are shown in Table 2.3. 
 
2.4 BIOPHYSICAL MEASUREMENTS 
 
The following measurements were made to all women included in the study 
 
 Maternal weight and height and subsequent calculation of the body mass 
index (BMI) in Kg/m2,  
 Stabilised measurement of MAP 
 Fetal crown-rump length in mm 
 Fetal Nuchal translucency in mm 
 Uterine artery PI of the two arteries 
  








Table 2.3 Maternal characteristics in the unaffected and in those delivering small for 







Maternal age in yrs, median (IQR) 
32.3 (28.0-
36.0) 
31.4 (26.3 – 
35.7)‡ 










Racial origin   
Causacian, n (%) 22.898 (73.1) 867 (56.4) ‡ 
African, n (%) 5.635 (18.0) 416(27.1) ‡ 
South Asian, n (%) 1.290 (4.1) 140 (9.1) ‡ 
East Asian, n (%) 600(1.9) 51(3.3) † 
Mixed, n (%) 891(2.8) 62(4.0)∗  
Parity   
Nulliparous, n (%) 14.746(47.1) 952(62) ‡ 
Parous with previous non-SGA neonate, n (%) 15.302(48.9) 409(26.6) ‡ 
Parous with previous SGA and non-SGA 
neonate, n (%) 
586(1.9) 62(4.0) ‡ 
Parous with previous SGA neonate, n (%) 680(2.2) 113(7.4) ‡ 
Cigarette smoker 2.483(7.8) 257(16.7) ‡ 
Conception   
Spontaneous, n (%) 30.163(96.3) 1,455(94.7) 
Assisted conception, n (%) 1.151(3.7) 81(5.3) ∗ 
Chronic hypertension, n (%) 297(0.9) 25(1.6) ∗ 
Pre-pregnancy diabetes mellitus, n (%) 235(0.8) 10(0.7) 
Comparisons between the SGA and the unaffected groups were by Chi-square or Fisher exact test for 
categorical variables and Mann-Whitney-U test for continuous variables: ∗ p < 0.05, † p < 0.001, ‡ p < 0.0001. 








2.4.1  Blood pressure 
 
The blood pressure was taken by validated automated devices (3BTO-A2, Microlife, 
Taipei, Taiwan; Reinders et al., 2005) that were calibrated before and at regular 
intervals during the study (every 1,000 inflations). The recordings were made by 
doctors who had received appropriate training on the use of these machines. Women 
were allowed to rest for 15–30 minutes and the BP measurements were taken in a 
quiet room with a temperature of between 20°C and 24°C. The women were in the 
seating position, with their arms supported at the level of the heart and either a small 
(< 22 cm), normal (22-32 cm) or large (33-42 cm) adult cuff was used depending on 
the mid-arm circumference (Pickering et al., 2005). The BP was measured in both 
arms simultaneously (Figure 2.1) and a series of recordings was made at 1-minute 
intervals until variations between consecutive readings fell within 10 mmHg in systolic 
BP and 6 mmHg in diastolic BP in both arms (National Heart Foundation of Australia, 
2004). When this point of stability was reached, we calculated the MAP of each arm 
as the average of the last two stable measurements and as recommended we took 
the arm with the highest final MAP and its measurements of systolic BP and diastolic 





















Figure 2.1 Simultaneous measurement of blood pressure in both arms    
 
            
 
 
2.4.2  Fetal CRL and NT measurements 
 
The measurement of fetal CRL and NT was performed as part of routine screening 
for chromosomal abnormalities in the first trimester of pregnancy. All screening was 
performed by Fetal Medicine Foundation-accredited operators following the 













2.4.3  Uterine artery Doppler  
 
Uterine artery pulsatility index (PI) was measured by transabdominal ultrasound by 
obtaining a sagittal section of the uterus, cervical canal and identifying the internal 
cervical os. Subsequently, colour flow mapping was used to identify the uterine 
arteries by insonating the lateral walls of the uterus. 
 




Pulsed wave Doppler was used to sample the uterine flow with the gate set at 2 mm 
to cover the whole vessel and an insonation angle of less than 30º. When three similar 
consecutive waveforms were obtained, the uterine artery PI was measured from the 
left and right arteries (Figure 2.3). The lowest PI value was used as it has been shown 


















All sonographers that participated in the study had obtained the Fetal Medicine 
Foundation Certificate of competence in obstetric Doppler imaging 
(http://www.fetalmedicine.com). The results of the Doppler studies were not given to 
the women or their doctors and did not influence the subsequent management of the 
pregnancies. 
 
2.5 BIOCHEMICAL MEASUREMENTS  
 
The following biochemical markers from maternal blood were evaluated for predicting 
an SGA neonate in the first trimester.  
 
 PAPP-A 





 Free T3,T4,TSH 
 









All women taking part in our study had a blood sample taken for the analysis of PAPP-
A and β-hCG which is part of the routine screening for chromosomal abnormalities. 
At the same time, Samples of serum and plasma were stored at -80C for subsequent 
biochemical analysis.   
 
In the case of PLGF, PP13, ADAM12, FT3, FT4 and TSH these markers were 
examined in case-controlled studies. The cases were drawn from the screening study 
population on the basis of availability of stored serum. The non-SGA cases were from 
singleton pregnancies with no history of thyroid disease, which did not develop PE 
and resulted in the live birth of phenotypically normal neonates with birth weight above 
the 5th percentile for gestational age.  The control cases were matched to the SGA 
cases for storage time. Data from the case controlled studies of PLGF, PP13 and 
ADAM 12 were included in previous publications (Poon et al., 2008a, Akolekar et al., 
2009; Poon et al., 2008b), while data on sENG, TSH, FT3, FT4 has not been 
published before. In this study, we combine all available data to develop an integrated 
algorithm for the early prediction of SGA in the absence of PE.  
 
2.5.1 PAPP-A & β-hCG 
 
Maternal serum pregnancy-associated plasma protein-A (PAPP-A) and β-hCG were 
measured using the DELFIA XPRESS analyzer (PerkinElmer Life and Analytical 
Sciences, Waltham, USA). In the case of PAPP-A, the variation of the DELFIA 
XPRESS PAPP-A assay was determined in 20 runs with two replicates using this 
DELFIA XPRESS system. The calibration curve of the first run was used as a 
reference curve during the 14-day-period. The intra-assay and inter-assay variations 
were 1.2% and 2.1%, respectively, at a PAPP-A concentration of 462 mU/L, 1.4% 
and 2.3% at 2124 mU/L and 1.3% and 2.5% at 5543 mU/L.  
 










Duplicate serum sample of 100 μL was used to measure PlGF concentration by a 
quantitative enzyme-
human PlGF immunoassay (R&D systems Europe Ltd., Abingdon, UK). The assays 
were performed on an automated ELISA processor (Dade-Behring BEP 2000, 
reader (PerkinElmer Life and Analytical Sciences, Turku, Finland) and PlGF 
concentrations were determined using Multi-Calc software (PerkinElmer Life and 
Analytical Sciences, Turku, Finland). The lower limit of detection of the assay was 7 
pg/mL and the between batch imprecision was 8.3% at a PlGF concentration of 48 
pg/mL, 5.6% at 342 pg/mL and 5.1% at 722 pg/mL. Samples whose coefficient of 




Serum PP13 was measured in maternal serum samples (25 μL/well in duplicate by 
DELFIA ® (Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) using 
research reagents (Perkin Elmer Life and Analytical Sciences, Turku, Finland). The 
concentration of PP13 measured was directly proportional to the fluorescence 
measured on a time-resolved fluorometer at 615 nm. The coefficient of variation (CV) 
was 4.1% at a PP13 concentration of 16.6 pg/mL, 2.0% at 60.4 pg/mL and 2.7% at 




A single serum sample of 25 microliters was used to measure ADAM12 concentration 
by a heterogeneous time-resolved fluorescent immunoassay, where ADAM12 
concentration was directly proportional to the fluorescence measured on a time-








resolved fluorometer at 615 nm (DELFIA/AutoDELFIA ADAM12 research kit, 
PerkinElmer Life and Analytical Sciences,Turku, Finland). Fresh aliquots of ADAM12 
quality control samples of 77.6, 294.4, and 736.2 pg/mL concentration were 
measured in duplicate at the beginning and at the end of each run. The mean 
coefficients of variation were 5.4%, 2.8%, and 3.2%, respectively.  
 
2.5.5 Soluble Endoglin 
 
Plasma sEng and serum PlGF were measured by enzyme-linked immunoassay 
technique using DuoSet® human sENG and Quantikine® human PlGF immunoassay 
(R&D Systems Europe Ltd., Abington, UK). The lower limits of detection of the assays 
were 5 pg/mL for sEng and 7 pg/mL for PlGF. Samples whose coefficient of variation 
of the duplicates exceeded 15% were re-analyzed.  
 
 
2.5.6 FT3, FT4, TSH 
 
The maternal serum concentrations of FT3, FT4 and TSH were measured by 
immunoassay using direct, chemiluminometric technology (Siemens Advia Centaur 
assays, Siemens Healthcare Diagnostics Ltd, Surrey, UK). The minimum detectable 
concentrations of FT3, FT4 and TSH were 0.3 pmol/L, 1.3 pmol/L and 0.003 mIU/L, 
respectively. The inta-assay coefficients of variation were 3.08%, 2.35% and 2.47% 
at FT3 concentrations of 2.9 pmol/L, 6.6 pmol/L and 14.2 pmol/L, respectively; 4.69%, 
2.31% and 2.22% at FT4 concentrations of 6.1 pmol/L, 13.9 pmol/L and 39.9 pmol/L, 
respectively; 2,48%, 2.44% and 2.41% at TSH concentrations of 0.74 mIU/L, 5.65 















2.6 OUTCOME MEASURES 
 
Data on pregnancy outcome were obtained from the maternity computerised records 
or the general medical practitioners of the women and were recorded in our database. 
The neonate was considered to be SGA if the birth weight was less than the 5th 
percentile for gestation at delivery, using a reference range derived from our 
population (Poon et al., 2010). Neonates with birth weight at or above the 5th 
percentile were classified as non-SGA. We excluded pregnancies with major fetal 
abnormalities, those ending in termination, miscarriage or fetal death before 24 
weeks, those with PE and cases with no pregnancy follow-up. We further stratified 
SGA cases between those delivering before and after 37 weeks of gestation.  
 
The severity of SGA is reflected in the gestation at delivery with most of the preterm 
SGA neonates being delivered due to iatrogenic reasons. The obstetric records of all 
women with an SGA pregnancy were examined to determine if there was no 
concomitant gestational hypertension or Preeclampsia. Similarly, for quality control, 




2.7 STATISTICAL ANALYSIS 
 
The distribution of birth weight was made Gaussian after logarithmic10 
transformation. Regression analysis was used to determine the association of birth 








weight with gestation at delivery (GA) and to establish a reference range with 
gestation (Figure 3.1, chapter 3).  
 
Baseline data for the outcome groups were summarised by the median and inter-
quartile range (IQR) and number (%) in Table 3.2 and comparisons between outcome 
groups were by Chi-square or Fisher exact test for categorical variables and by 
Mann–Whitney U test for continuous variables, both with posthoc Bonferroni 
correction (critical statistical significance *p<0.0167). Multivariate logistic regression 
analysis was used to determine the factors amongst the maternal characteristics with 
significant contributions in predicting SGA. 
 
The patient-specific risk for the SGA group is calculated from the formula: odds / 
(1+odds), where odds = eY. Y is derived from logistic regression analysis of factors 
amongst the maternal characteristics, medical and obstetric history in predicting 
pregnancies delivering an SGA neonate. The performance of screening for SGA by 
maternal characteristics was estimated by receiver operating characteristic (ROC) 
curves (chapter 3). 
 
In each patient in the SGA and non-SGA groups above biophysical and biochemical 
markers were measured as described, comparisons between the groups were 
conducted by X2 or Fisher’s exact test for categorical variables and by Mann-Whitney 
U test for continuous variables and Gaussian distributions were fitted. These fitted 
distributions define the likelihood ratios for the screening tests that can be combined 
with the prior risk to produce a posterior risk. The performance of screening by the 
above markers was compared by the areas under the ROC curves (AUROC) (Zweig 
and Campbell, 1993) (Chapters 3,4,5&6) 
 
Subsequently the biophysical and biochemical markers were simulated for 500,000 
pregnancies from the SGA populations and the non-SGA distributions. For the 








markers this involved sampling from the fitted multivariate Gaussian distributions. For 
the prior risks, this involved drawing samples, with replacement, 500,000 records from 
the screening samples of SGA and non-SGA pregnancies. These records were then 
used to define maternal factors related a priori risks for SGA that were multiplied by 
the likelihood ratios of the biophysical and biochemical markers to derive the a-
posterior risks in simulated samples of 500,000 SGA and 500,000 non-SGA 
pregnancies. The a priori and a posteriori risks in the SGA and non-SGA groups were 
used to calculate the detection rates at fixed false positive rates of 5 and 10%. The 
process of sampling with replacement from the SGA and non-SGA screening data 
means that the modelled screening performance reflects the screening population. 
The samples of 500,000 were chosen to make the error resulting from the simulation 
negligible. (Chapter 6) 
 
The statistical software package SPSS 16.0 (SPSS Inc., Chicago, Ill., USA) was used 
for data analyses. Monte-Carlo simulations were programmed in R (The R Foundation 















CHAPTER 3. DEFINING SMALL FOR GESTATIONAL AGE 
 
ABSTRACT 
Objective: Firstly, to establish a reference range of birth weight with gestation at 
delivery and to identify maternal characteristics significantly associated with birth 
weight. 
 
Method: In 33,602 women with singleton pregnancies at 11 weeks to 13 weeks 6 
days maternal demographic characteristics and medical history were recorded. 
Regression analysis was used to determine the association of birth weight with 
gestation at delivery and to establish a reference range with gestation. Logistic 
regression analysis was used to determine if maternal factors contribute significantly 
in predicting SGA in the absence of preeclampsia. 
 
Results: Birth weight increased with maternal weight and height; it was higher in 
parous than in nulliparous women and in those with a medical history of pre-
pregnancy diabetes mellitus, and it was lower in cigarette smokers, in all racial groups 
other than in Caucasian women, and in those with a medical history of chronic 
hypertension and in those who previously delivered SGA neonates.  
 
Conclusion: Prediction of the birth of SGA neonates in the absence of preeclampsia 
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Birth weight is affected by gestational age at delivery and several maternal 
characteristics, including racial origin, age, body mass index, parity and cigarette 
smoking (Gardosi et al., 1995a; Wen et al., 1990; Clausson et al., 1998; Gardosi, 
2006).  
 
The aims of this study in a population of more than 30,000 singleton pregnancies 
attending for routine care at 11-13 weeks were to establish a reference range of birth 
weight with gestation at delivery and to identify maternal characteristics that were 
significantly associated with birth weight. 
 
3.2 PATIENTS AND METHODS 
 
This was a prospective screening study for adverse obstetric outcomes in women 
attending for their routine first hospital visit in pregnancy at 11-13 weeks of gestation. 
See Chapter 2 for a description of the population, data collection, and outcome 
measures. 
 
Patients were asked questions on maternal age, racial origin (Caucasian, African, 
South Asian, East Asian and mixed), method of conception (spontaneous or assisted 
conception requiring the use of ovulation drugs), cigarette smoking during pregnancy 
(yes or no), history of chronic hypertension (yes or no), history of type 1 or 2 diabetes 
mellitus (yes or no) and obstetric history including parity (parous or nulliparous if no 
previous pregnancies at or after 24 weeks) and birth weight of previous neonates 
(only SGA, only non-SGA, or mixture of SGA and non-SGA). The answers were 
documented by a doctor and the maternal weight and height were measured.  
 








During the study period (March 2006 to September 2009) first-trimester combined 
screening for aneuploidies was carried out in 36,743 singleton pregnancies. We 
excluded 3,141 (8.5%) cases because they had missing outcome data (n=2,005), or 
the pregnancies resulted in miscarriage before 24 weeks of gestation (n=431), they 
were terminated or they resulted in the birth of babies with major defects (n=649), 
they were terminated for maternal psychosocial indications (n=56) (n=1,136). 
Statistical analysis was performed in the remaining 33,602 pregnancies. 
 
3.2.1 Statistical analysis 
 
The distribution of birth weight was made Gaussian after logarithmic10 
transformation. Regression analysis was used to determine the association of birth 
weight with gestation at delivery (GA) and to establish a reference range with 
gestation. The neonate was considered to be SGA if the birth weight was less than 
the 5th percentile for GA. Multivariate logistic regression analysis was used to 
determine the factors amongst the maternal characteristics with significant 
contributions in predicting SGA. The performance of screening was estimated by 
receiver operating characteristic (ROC) curves.  
 
The statistical software package SPSS 15.0 (SPSS Inc.,Chicago, IL) and Medcalc 



















3.3.1 Birth weight corrected for gestation at delivery 
 
In the total population of 33,602 pregnancies there was a significant association 
between birth weight and gestation at delivery (Figure 3.1):  
 
Expected log10 birth weight  = -0.63294048133589 + 0.187282402775684 x (GA) - 
0.00207767621420371 x (GA)2; R2=0.574, SD=0.058051, p<0.0001. 
 
Figure 3.1 Relationship between birth weight and gestational age at delivery with 95th, 
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3.3.2 Birth weight and maternal characteristics 
 
Multivariate linear regression analysis demonstrated that for log10 birth weight 
significant independent contributions were provided by GA, weight , height, smoking 
status, parity, racial origin, medical history of chronic hypertension and pre-pregnancy 
diabetes mellitus (R2=0.625, SD=0.054439, p<0.0001; Table 3.1). 
 
3.3.3 Prediction of small for gestational age neonates 
 
In 752 (2.2%) of the 33,602 pregnancies, there was preeclampsia and these were 
excluded from further analysis. In 1,536 (4.7%) of the 32,850 pregnancies, the 
neonatal birth weight corrected for GA was below the 5th percentile. The maternal 
characteristics of the SGA and unaffected pregnancies are shown in Table 3.2.  
 
Comparisons between the SGA and the unaffected groups were by Chi-square or 
Fisher exact test for categorical variables and Mann-Whitney-U test for continuous 
variables: *p<0.05, †p<0.001, ‡p<0.0001. 
 
The risk for SGA was calculated from the formula: odds / (1+odds) where odds= eY. Y 


















Table 3.1 Linear regression analysis for the prediction of log10 birth weight by 





   
b SE p 
Intercept -0.935219 0.042717 <0.0001 
GA 0.186853 0.002072 <0.0001 
(GA)2 -0.002078 0.000028 <0.0001 
Weight 0.003726 0.000622 <0.0001 





Height 0.000965 0.000048 <0.0001 
Age 0.001466 0.000441 0.0009 
(Age)2 -0.000026 0.000007 0.0002 
Parous 0.016986 0.000631 <0.0001 
Smoking -0.024867 0.001116 <0.0001 
Racial origin    
   Caucasian 0   
   African -0.021769 0.000809 <0.0001 
   South Asian -0.017824 0.001503 <0.0001 
   East Asian -0.005543 0.002176 0.011 
   Mixed -0.009063 0.001788 <0.0001 
Chronic hypertension  -0.020995 0.002834 <0.0001 
Diabetes 0.031430 0.003438 <0.0001 
Assisted conception -0.004015 0.001581 0.011 








Table 3.2 Maternal characteristics in the unaffected and in those delivering small for 






Maternal age in yrs, median (IQR) 32.3 (28.0-36.0) 31.4 (26.3-35.7)‡ 
Weight in Kg, median (IQR) 66.0 (59.0-75.0) 61.1 (55.0-70.0)‡ 




Racial origin   
   Caucasian, n (%) 22,898 (73.1) 867 (56.4)‡ 
   African, n (%) 5,635 (18.0) 416 (27.1)‡ 
   South Asian, n (%) 1,290 (4.1) 140 (9.1)‡ 
   East Asian, n (%) 600 (1.9) 51 (3.3)† 
   Mixed, n (%) 891 (2.8) 62 (4.0)* 
Parity   
   Nulliparous, n (%) 14,746 (47.1) 952 (62.0)‡ 
   Parous with previous non-SGA neonate, 
n (%) 
15,302 (48.9) 409 (26.6)‡ 
   Parous with previous SGA and non-SGA 
neonate, n (%) 
586 (1.9) 62 (4.0)‡ 
   Parous with previous SGA neonate, n (%) 680 (2.2) 113 (7.4)‡ 
Cigarette smoker, n (%) 2,483 (7.8) 257 (16.7)‡ 
Conception   
   Spontaneous, n (%) 30,163 (96.3) 1,455 (94.7) 
   Assisted conception, n (%) 1,151 (3.7) 81 (5.3)* 
Chronic hypertension, n (%) 297 (0.9) 25 (1.6)* 
Pre-pregnancy diabetes mellitus, n (%) 235 (0.8) 10 (0.7) 
Comparisons between the SGA and the unaffected groups were by Chi-square or Fisher 
exact test for categorical variables and Mann-Whitney-U test for continuous variables: ∗ p 
< 0.05, † p < 0.001, ‡ p < 0.0001 
 








Table 3.3 Logistic regression analysis for the prediction of small for gestational age by 
maternal factors 
 
Independent variable OR 
Age (per year) 1.659 95%CI P 
(Age)2 0.983 1.152-2.389 0.006 
(Age)3 1.000 0.971-0.994 0.004 
Weight (per kg) 0.781 1.000-1.000 0.002 
(Weight)2 1.003 0.696-0.876 <0.0001 
Weight)3 1.000 1.001-1.004 0.001 
Height (per cm) 0.968 1.000-1.000 0.005 
Racial origin  0.960-0.977 <0.0001 
Caucasian 1  <0.0001 
African 2.292 2.010-2.615  
South Asian 2.129 1.742-2.602 <0.0001 
East Asian 1.456 1.742-2.602 <0.0001 
Mixed 1.702 1.070-1.982 0.017 
Cigarette smoking 2.736 1.296-2.237 <0.0001 
Assisted conception 1.481 2.350-3.186 <0.0001 
History of chronic hypertension 1.683 1.160-1.893 0.002 
Parity  1.087-2.605 <0.0001 
Nuliparous (reference) 1   
Parous with previous SGA 1.823   
Parous with previous SGA and non-SGA 1.054 1.464-2.270 <0.0001 
Parous with previous non-SGA 0.392 0.795-1.398 0.715 












Performance of screening 
 
The area under receiver operating curve (AUROC) for the detection of SGA in 
screening by maternal factors is illustrated in Figure 3.2. The AUROC was 0.719 (95% 
CI 0.706-0.732). The detection rates were 21.0% and 34.0% at false positive rates of 
5% and 10%, respectively 
 
Figure 3.2 Receiver operating characteristics curve of maternal factors in the prediction 




























This study has established a reference range of birth weight for gestation in a large 
heterogeneous inner-city population of singleton pregnancies in which gestational 
age was determined by an ultrasound scan in early pregnancy. Birth weight is 
significantly influenced by maternal characteristics such as racial origin, weight, 
height, parity, cigarette smoking and medical history of chronic hypertension and pre-
pregnancy diabetes mellitus.  
 
Birth weight increased with maternal weight and height, it was higher in parous than 
in nulliparous women and in those with a medical history of pre-pregnancy diabetes 
mellitus, and it was lower in cigarette smokers, in all racial groups other than in 
Caucasian women and in those with a medical history of chronic hypertension. The 
risk for SGA decreased with maternal weight and height and increased with maternal 
age and in cigarette smokers, nulliparous women, in women of all racial groups other 
than Caucasians, in those with a medical history of chronic hypertension and in 
women who had assisted conception. The associations between birth weight and 
maternal characteristics such as age, weight, parity, racial origin, and cigarette 
smoking have been extensively reported (Gardosi et al., 1995; Wen et al., 1990; 
Clausson et al., 1998; Gardosi, 2006). It is recognized that it is necessary to adjust 
the birth weight for these maternal variables to establish appropriate growth standards 
in order to define growth abnormalities (Gardosi et al., 1992; Gardosi et al., 1995).  
 
In our screening study of over 30,000 singleton pregnancies for SGA in the absence 
of preeclampsia we chose 11-13 weeks as the gestation for screening because this 
is often the first hospital visit of pregnant women at which combined sonographic and 
biochemical testing for chromosomal and other major defects is carried out (Snijders 
et al., 1998; Kagan et al., 2008). At this visit, maternal characteristics are recorded, 








an ultrasound scan is carried out to confirm the gestation, screen for major defects 
and measure fetal NT, and maternal blood is taken for the measurement of free ß-
hCG and PAPP-A. Combining maternal characteristics with sonographic and 
maternal serum biochemical markers provides effective early screening for both 
chromosomal abnormalities and the development of preeclampsia with a detection 
rate of about 90% at a false positive rate of 5% (Poon et al., 2009).  
 
There is currently no effective method of early screening for SGA in the absence of 
preeclampsia. This study demonstrated that a combination of maternal demographic 
characteristics and medical history can detect 34% of pregnancies that subsequently 
deliver SGA neonates, at a false positive rate of 10%. When considering the AUROC 
value of 0.719 it is evident that the detection capabilities of maternal characteristics 
used in isolation would be a poor test for SGA. The extent to which a substantial 
increase in the performance of screening for SGA can be achieved by a combination 
of maternal factors with a series of biochemical and biophysical parameters will be 
investigated in the subsequent chapters of this thesis. 









CHAPTER 4. BIOPHYSICAL MARKERS AT 11-13 WEEKS IN 




Objective: To develop a model for prediction of small-for-gestational age (SGA) 
neonates in the absence of preeclampsia (PE) based on maternal factors and 
biophysical markers at 11-13 weeks’ gestation. 
 
Method: Screening study in 1,536 SGA and 31,314 non-SGA pregnancies based on 
maternal characteristics, fetal nuchal translucency (NT) thickness, mean arterial 
pressure (MAP) and uterine artery pulsatility index (PI). Regression analysis was 
used to develop a model for the prediction of SGA. 
 
Results: In the SGA group, uterine artery PI and MAP were increased and fetal NT 
was decreased. By using a combination of all biophysical markers in addition to 
maternal factors the detection rate for SGA was 25.5% for FPR of 5% and 37.7% for 
FPR of 10%. Screening performance with all biophysical markers for SGA< 37 weeks 
was 33.7% for FPR of 5% and 46.8% for FPR of 10%. 
 
Conclusion: Prediction of the birth of SGA neonates in the absence of preeclampsia 
can be provided in the first trimester of pregnancy by a combination of maternal 
characteristics, fetal nuchal translucency (NT) thickness, mean arterial pressure 
(MAP) and uterine artery pulsatility index (UAPI).  
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Histological studies reported that in pregnancies complicated by preeclampsia (PE) 
and SGA without PE there is evidence of impaired placentation characterized by 
inadequate trophoblastic invasion of the maternal spiral arteries (Sheppard et al., 
1981; Khong et al., 1986; Pijnenborg et al., 2006). PE, which is commonly associated 
with SGA, can now be predicted effectively at 11-13 weeks’ gestation by algorithms 
combining maternal characteristics with uterine artery pulsatility index (PI) and mean 
arterial pressure (MAP) (Akolekar et al., 2010). Screening for PE can be performed 
concurrently with screening for chromosomal abnormalities with the use of NT and 
maternal characteristics.  
 
Markers available from screening for chromosomal abnormalities and pre-eclampsia 
likely hold value in the prediction of SGA in the absence of PE. Already promising 
evidence exists for the use of uterine artery Doppler studies in the prediction of SGA 
from the first trimester (Dugoff et al., 2005; Poon et al., 2008). MAP has not been 
evaluated in the prediction of SGA without PE as yet and one study has raised the 
possibility for an association between fetal nuchal translucency thickness (NT) and 
birth weight; however, the available published data regarding this possible association 
is limited (Kelecki et al., 2005). 
 
We performed a screening study for the evaluation of biophysical markers obtained 














4.2 PATIENTS AND METHODS  
 
This was a prospective screening study for adverse obstetric outcomes in women 
attending for their routine first hospital visit in pregnancy at 11-13 weeks’ of gestation. 
See Chapter 2 for a description of the population, data collection, and outcome 
measures. 
 
Maternal history was recorded on a computerized system during the consultation. BP 
was measured by automated devices (poon et al., 2010) and transabdominal colour 
Doppler ultrasound was used to visualise the left and right uterine artery, measure 
the PI in each vessel and calculate the mean PI as previously described (chapter 2). 
The performance of screening for SGA by combinations of disease-specific maternal 
factor-derived a priori risk with UAPI, MAP and NT was determined. 
 
In the case of uterine artery PI and MAP, we used data from the screened population 
in which these biophysical measurements were recorded. 
 
4.2.1 Statistical analysis 
 
In each patient in the SGA and non-SGA groups the measured uterine artery PI and 
MAP were converted to multiples of the expected normal median (MoM) corrected for 
fetal CRL, maternal age, weight, smoking, parity, racial origin and method of 
conception as described in previous studies (Akolekar et al., 2010, Kagan et al., 
2008).  
 
The measured NT was expressed as a difference from the expected normal mean for 
gestation ( Δ value) (Wright et al., 2008).  










For MAP Multiple regression analysis of the unaffected group in previous studies 
demonstrated that for log10 MAP, significant independent contributions were provided 
by fetal crown-rump length (CRL), maternal body mass index (BMI), age, smoking 
and racial origin (Poon et al., 2010). The formula below was used in each patient to 
derive the expected log10 MAP and then expressed the observed values as multiples 
of the expected median (MoM). 
 
Log10 expected MAP = 1.861313 - 0.000178 x CRL in mm + 0.002572 x BMI in Kg/m2 
+ 0.000426 x Age in years + (-0.008440 if smoking, 0 if no smoking) + (-0.004583 if 
African race, -0.004449 if South Asian race, -0.010079 if East Asian race, -0.006255 
if Mixed); R2=0.112, p<0.0001. 
 
For uterine artery PI multivariate regression analysis in the unaffected group 
demonstrated that for mean log10 uterine artery PI significant independent 
contributions were provided by fetal CRL, maternal BMI, age and racial origin. In each 
patient, we used the formula below to derive the expected log uterine artery PI and 
then expressed the observed value as a MoM of the expected value. 
 
Log10 expected uterine artery PI (mean) = 0.404278 - 0.002080 x CRL in mm – 
0.001826 x BMI in Kg/m2 – 0.000735 x Age in years + (0.021656 if African race, 
0.019438 if Mixed, 0 if other racial origins); R2=0.028, p<0.0001. 
 
Comparisons between the SGA and non-SGA groups were conducted by x2 or 
Fisher’s exact test for categorical variables and by Mann-Whitney U test for 
continuous variables. 
 









The Mean MoM values for the unaffected and SGA groups are summarized in table 
4.1 
 
Subsequently the biophysical and biochemical markers were simulated for 500,000 
pregnancies from the SGA populations and the non-SGA distributions as described 
in chapter 2. The a priori and a posteriori risks in the SGA and non-SGA groups were 
used to calculate the detection rates at fixed false positive rates of 5 and 10%. 
 
4.3 RESULTS 
Uterine artery PI was measured in 19,957 Non-SGA pregnancies and 1,133 SGA 
pregnancies and was found to be significantly increased in all three SGA groups. The 
difference was greater for the SGA<37 group.  
 
MAP was measured in 12,854 non-SGA and 661 SGA pregnancies and was found to 
be significantly increased in the all-SGA and SGA ≥ 37 groups. 
 
NT was measured in the whole screened population (31,314 non-SGA and 1,133 non-
SGA) and was found to be decreased in all three SGA groups but was only significant 


















Table 4.2 Median and interquartile range (IQR) of uterine artery PI, MAP and NT 














Non-SGA All SGA 
SGA < 
37wks 
SGA ≥ 37wks 
 n MoM n MoM n MoM n MoM 
















































Comparisons between the SGA and the non-SGA groups by Mann-Whitney U test. 
Significance level * p < 0.00001, † p < 0.01, ‡ p < 0.025. 









Figure 4.1 Box plot with median, interquartile range and 95% CI for uterine artery PI 




p < 0.00001 
p < 0.00001 









Figure 4.2 Box plot with median, interquartile range and 95% CI for mean arterial 




p < 0.00001 









Figure 4.3 Box plot with median, interquartile range and 95% CI forΔ-NT in the non-
SGA group and in those delivering SGA neonates 
 
 
p < 0.00001 









4.3.1 Performance of screening 
 
The detection rates for Maternal factors plus uterine artery PI were 23.9% for a FPR 
of 5% and 35.9% for FPT of 10%. For Maternal factors plus MAP was 22.5% and 
34.5% and for NT was 21.8% and 33.9% respectively. By using all biophysical 
markers in addition to maternal factors the detection rate increases to 25.5% for FPR 
of 5% and 37.7% for FPR of 10%. The results were also analysed by stratifying SGA 
to <37 weeks and ≥ 37weeks. The detection rate of maternal factors plus all 
biochemical factors for SGA< 37 weeks was 33.7% for FPR of 5% and 46.8% for FPR 
of 10%. The breakdown of screening performance is summarized in table 4.3. 
 
Table 4.3 Performance of screening for delivery of SGA neonates by maternal factors 
only, maternal factors with uterine artery pulsatility index, mean arterial pressure and 




ALL SGA SGA<37 weeks SGA >37 weeks 
 DR for FPR 
5% 










Maternal factors 21.0 34.0 23.3 35 20.8 33.9 
Maternal factors 
plus 
      
Uterine artery PI 23.9 35.9 32 44.5 23.1 34.9 
MAP 22.5 34.5 22.6 34.6 22.6 34.6 
NT 21.8 33.9 22.5 34.5 22.0 33.6 
Biophysical 
markers 
25.5 37.7 33.7 46.8 24.3 36.8 
DR = Detection rate; FPR = false positive rate 













The data confirm the results of previous studies and indicate that, as in the case of 
PE, in pregnancies with SGA in the absence of PE there is evidence of increased 
placental resistance and possible impairment of function from the first trimester of 
pregnancy demonstrated by an increased UAPI in the SGA group. However, the 
magnitude of such impairment is considerably less than in PE. These observed 
differences have been seen repeatedly in similar studies and the reason for this is 
likely to be multifactorial with three predominant explanations.  
 
First, use of SGA as a proxy for FGR is not ideal; with studies reporting that up to 
50% of growth-restricted neonates can be born with a birthweight above the 10th 
centile (Breeze & Lees 2007). In a recent study from the same population Akolekar 
et al., showed that addition of UAPI to maternal factors improved the prediction of 
Early PE (<34wks) from 33% to 54.1% for FPR of 5% (Akolekar et al., 2010), in 
contrast to the more modest increase from 23% to 33% for severe SGA (<37wks) for 
the same FPR. Similar effects have been seen in another study where the sensitivity 
of screening only by uterine artery Doppler (UAD) in the first trimester was highest for 
SGA with PE compared with SGA without PE (Melchiorre et al., 2009). Interestingly 
in the same study, the investigators attempted to differentiate true FGR from 
constitutional SGA by evaluating third-trimester Dopplers and considering those 
pregnancies that required iatrogenic preterm delivery. They showed a graded 
increase in the sensitivity of UAD (24.5% for FGR and 37.5% for preterm FGR) 
supporting the notion that the decreased performance on UAD in the SGA group 









might represent the “dilution effect” of the outcome group by a large number of 
normal-small pregnancies.  
 
Second, the observed difference in UAD screening can be attributed to fundamental 
pathophysiological differences between FGR and PE (Goswami et al., 2006). 
Evidence of structural differences between cases of isolated SGA and PE has been 
described in the literature, however, a robust mechanism to explain these differences 
does not exist. In a study examining placentas from pregnancies with PE, PE with 
SGA and isolated SGA it was shown that isolated SGA had significantly smaller 
placentas with a reduction in the total area occupied by the villi. In PE, with and 
without FGR, the total area occupied by villi or intervillous space was not altered 
(Daayana et al., 2004).  At the same time in vitro studies of pure cytotrophoblast show 
strong differences between the patterns of differentiation of cells cultured from isolate 
FGR, FGR with PE and PE alone (Newhouse et al., 2007). These pathophysiological 
differences have also been seen in chorionic villi of cases obtained in the first 
trimester after Chorionic villous sampling (Huisman et al., 2010). However in order to 
move these observations into a more robust theory around the causation of FGR and 
PE one would need to correlate these observed pathophysiological differences with 
the presence or absence of increased UA resistance through obtaining chorionic villi 
from the first trimester of pregnancy and prospectively investigating the outcomes of 
pregnancies that are seen to have high UA resistance, something which by no doubt 
is challenging from a methodological point of view. In a recent study a similar but 
more simplified technique for the investigation of early placental samples has been 
described, where samples from first-trimester elective terminations are separated by 
examining UA resistance (Fraser et al., 2012). This technique although useful in the 
investigation of early pathophysiological changes in placentas with inadequate 
trophoblast invasion still would not be able to the differential between SGA and PE 
due to the obvious lack of knowledge of the final outcome.  










Third, it is possible that the phenomenon of a differential maternal response to 
inadequate trophoblast invasion is due to the presence or absence of the metabolic 
syndrome (Ramsay et al., 2004).  Observations between the PE and isolated SGA 
populations between the SGA study and the PE screening study from the same 
population mentioned before show that the PE population has a higher mean 
maternal weight (70kg vs 61kg) supporting in part the metabolic syndrome theory 
(Akolekar et al., 2010).  
 
MAP was found to be significantly raised in the SGA group at the time of screening 
even if subsequently the subjects did not develop gestational hypertension or PE. 
Again the effect seems to be much less prominent when compared with PE. It is 
possible that the degree of vasculopathy has not exceeded the thresholds for the 
development of PE in later pregnancy but still some degree of hypertension is present 
in the first trimester. Another consideration for the association identified is that a 
proportion of these cases are undiagnosed chronic hypertension cases. Chronic 
hypertension is a well-recognized risk factor for SGA and our classification of chronic 
hypertension depends on maternal reporting. It is possible that some of the subjects 
did not volunteer this information or hypertension has not been picked up in those 
that had their booking appointment prior to the first-trimester scan. Another 
explanation can be that the technique that we follow as part of our research project is 
likely to be more thorough and consistent than blood pressure measurements 
performed in midwifery booking visits. Irrespective of the cause, measurement of 
MAP in the first trimester has a small but significant correlation with SGA and can be 
used as part of the screening algorithm. 
 
We also report a negative correlation between NT and fetal growth. Similar results 
have been found in another study (aOR of 0.57(0.38—0.86) (Papastefanou et al., 









2011). The association is weak with minimal value in the overall prediction but non-
the-less statistically significant. Published data on the association between fetal NT 
and birth weight are confined to only one study, which reported that an increased fetal 
NT in euploid pregnancies is associated with macrosomia (Kelecki et al., 2005). The 
suggested underlying pathophysiology for this association is that enhanced capillary 
permeability, resulting in an increase in fetal NT, may be a result of maternal 
hyperglycemia, which by itself may increase birth weight (Bartha et al., 2003; Kelecki 
et al., 2005). Whether the reverse of this hypothesis may provide a possible reason 
for our findings remains to be established. Given the availability of the NT 
measurement at the same time of the application of the screening algorithm, we 
advocate its use.  
 
Overall it has been shown that the use of the above biophysical markers in 
combination with the a-priori derived risk for SGA in pregnancy can improve the 
detection algorithm especially for those pregnancies that suffer from severe SGA 
requiring delivery before 37 weeks. It also verifies results of previous studies that 
show a degree of inadequate placentation reflected by increased resistance to blood 
flow. Given that all the above measurements are recommended for screening for PE 
and some are already widely used for screening for aneuploidies it is logical that they 
are applied concurrently for the prediction of SGA. Further improvement in screening 













CHAPTER 5. BIOCHEMICAL MARKERS AT 11-13 WEEKS IN 





Objective: To develop a model for prediction of small-for-gestational age (SGA) 
neonates in the absence of preeclampsia (PE) based on maternal factors and 
biochemical markers at 11-13 weeks’ gestation. 
 
Method: Screening study in 1,536 SGA and 31,314 non-SGA pregnancies based on 
maternal characteristics, PAPP-A, β-hCG and a series of case-controlled studies on 
PLGF, PP13, sENG, FT3, FT4 and TSH. Regression analysis was used to develop a 
model for the prediction of SGA. 
 
Results: In the SGA group, serum PAPP-A, β-hCG, PLGF and PP13 were 
significantly decreased while no difference was found for sENG, FT3, FT4 and TSH. 
The performance of screening for the combination of the above markers showed a 
DR of 30% for a FPR 5% for all-SGA and 50% respectively for SGA<37wks. 
 
Conclusion: Screening performance for the delivery of an SGA neonate can be 
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There is growing evidence that birth weight is related to placental function in early 
pregnancy. The complex process of early placentation and subsequent placental 
function is thought to involve a multitude of processes regulated by a variety of 
signalling molecules, angiogenic factors, and other growth factors. We performed a 
thorough review of the current literature and identified markers that have shown 
promise in the detection of placental insufficiency (chapter 1). Some markers have 
been shown to have a value in the early prediction of PE but evidence for the 
association with normotensive SGA tends to be less available. 
 
Several studies reported that in pregnancies delivering small-for-gestational-age 
(SGA) neonates, serum PAPP-A at 11 to 13 weeks’ was decreased (Ong et al., 2000; 
Smith et al., 2002; Yaron et al., 2002; Tul et al., 2003; Dugoff et al., 2004; Smith et 
al., 2006; Canini et al., 2008; Spencer et al., 2008; Fox et al., 2009; Law et al.,2009; 
Montanari et al., 2009; Pihl et al., 2009). At the same time, other placental growth 
factors have shown promising evidence as markers of placental function in the first 
trimester.  PP13 and ADAM12 are thought to be involved in growth regulation of the 
placenta and an association with SGA neonates has been reported in previous 
studies (Chafez et al., 2007; Cowans et al., 2008; Matwejew et al., 2010, Poon et al., 
2008). 
 
Angiogenic factors have featured a central role in pathophysiological theories of PE 
and FGR. The most widely investigated molecule is PLGF, low levels of which have 
been associated with placental insufficiency in both the presence and absence of PE 
(Thadhani et al., 2004; Smith et al., 2007; Erez et al., 2008; Poon et al., 2008). Soluble 
endoglin (sENG) which is an anti-angiogenic factor has also been reported to be 









increased in PE and is thought to reflect an anti-angiogenic state with only limited 
results of value in normotensive SGA (Erez et al., 2008).  
 
Both In-vitro studies (Barber et al., 2005; Oki et al., 2004) and some clinical studies 
have reported an association with thyroid hormones (TSH, FT3, FT4), placental 
function and birthweight (Leung et al., 1993; Levine et al., 2009; Sahu et al., 2010). 
There is also contradictory evidence that clinical and subclinical hypothyroidism is 
associated with increased risk for both PE and the birth of SGA neonates in the 
absence of PE (Blazer et al., 2003; Casey et al., 2007; Allan et al., 2000). In a recent 
study it has been reported that in pregnancies that develop PE, maternal serum 
thyroid stimulating hormone (TSH) at 11-13 weeks’ gestation was higher and free 
thyroxine (FT4) was lower than in normotensive controls (Ashoor et al., 2010). 
 
We choose to investigate the above markers based on promising preliminary results 
from our group or other studies and also based on availability of stored samples and 
analytic assays. We bring together results from previous case-control studies 
performed from our group for some of these markers (PAPP-A, PLGF, ADAM12, 
PP13) and also investigate the value of some additional biochemical markers (sENG, 
TSH, FT3, FT4) and examine their combined predictive value in the prediction of SGA 
in the first trimester. 
 
5.2 PATIENTS AND METHODS  
This was a prospective screening study for adverse obstetric outcomes in women 
attending for their routine first hospital visit in pregnancy at 11-13 weeks of gestation. 
(See Chapter 2 for description of the population, data collection and outcome 
measures and measurement methodology of the individual markers.) 
 









5.2.1 Statistical analysis 
 
The measured maternal serum PAPP-A and β-hCG were converted to multiples of 
the expected normal median (MoM) corrected for fetal CRL, maternal age, weight, 
smoking, parity, racial origin and method of conception as previously described 
(Kagan et al., 2008a).  
 
The measured concentration of PLGF was log transformed to make the distribution 
Gaussian. Multiple regression in a previous study demonstrated that for log PLGF 
significant independent contributions were provided by fetal CRL, maternal weight, 
smoking and racial origin. (Akolekar et al., 2008). In each patient, we used the formula 
below to derive the expected log PLGF and then expressed the observed value as a 
MoM of the expected value. 
 
log expected PlGF = 1.150 + (0.008 × CRL in mm)−(0.002 × weight in kg)+ (0.199 if 
smoker, 0 if not)+ (0.177 if African-American, 0.100 if Indian or Pakistani, 0 if other 
racial origin); r2 = 0.237, P < 0.0001. 
 
The measured concentration of PP13 was log transformed to make the distribution 
Gaussian. Multiple regression in a previous study demonstrated that for log PP13 
significant independent contributions were provided by maternal weight and smoking 
(Akolekar et al., 2009). In each patient, we used the formula below to derive the 
expected log PP13 and then expressed the observed value as a MoM of the expected 
value. 
 
log expected PP13 = 2.089 − 0.004× maternal weight in kilograms + (−0.214 if 
smoker, 0 if non-smoker); R2 = 0.154, p < 0.0001. 
 









The measured concentration of ADAM12 was log-transformed to make the 
distribution Gaussian. Multiple regression analysis in the control group demonstrated 
that for log ADAM12, significant independent contributions were provided by fetal 
CRL, maternal weight, and racial origin. In each patient, we used the formula below 
to derive the expected log ADAM12 and then expressed the observed value as a 
MoM of the expected value. 
 
log expected ADAM12 = 2.789 − 0.005× maternal weight in kilograms + (0.006 x CRL 
in mm) + (0.040 if African-American, 0 if other racial origin); R2 = 0.272, p < 0.001. 
 
The measured sENG concentration was made Gaussian using the following 
transformation: Y = log10 (sEng−10,000). The data could not be made Gaussian by 
more standard transformations, such as log10 or square root. Distributions were 
confirmed to be Gaussian using the Kolmogorov–Smirnov test. Multiple regression 
analysis in the control group demonstrated that for Y significant contribution was 
provided by fetal CRL and maternal weight. In each patient, we used the formula 
below to derive the expected logsENG and then expressed the observed value as a 
MoM of the expected value.  
 
Log10 (sENG-10,000) = 4.9327234491 + (-0.0025306978 x CRL in mm) + (-
0.0024068511 x maternal weight in kilograms) R2 = 0.106 p < 0.001. 
  
The measured concentrations of FT3, FT4 and TSH were converted to multiples of 
the expected normal median (MoM) corrected for gestational age and maternal age, 
racial origin, and body mass index. We reported previously that serum TSH increases 
whereas FT3 and FT4 decrease with gestational age and all three are lower in women 
of African racial origin than Caucasians, serum FT3, and FT4 decrease but TSH does 
not change significantly with maternal age and serum TSH and FT3 increase whereas 









FT4 decreases with body mass index (Ashoor et al., 2010). The SGA and unaffected 
groups were compared for median TSH MoM, FT3 MoM and FT4 MoM using the 
Mann-Whitney test and for the proportion of cases with serum TSH above the 97.5th 
percentile and serum FT3 and FT4 below the 2,5th percentile by the Chi-square test.  
 
All mean MoM values for the unaffected and SGA groups are summarized in table 
5.1. 
 
Subsequently the biophysical and biochemical markers that were found to be 
predictive of SGA were simulated for 500,000 pregnancies from the SGA populations 
and the non-SGA distributions as described in chapter 2. The a priori and a posteriori 
risks in the SGA and non-SGA groups were used to calculate the detection rates at 




PAPP-A and β-hCG were measured in the whole screened population (31,314 non-
SGA and 1,536 non-SGA) and were found to be significantly reduced in all three SGA 
groups apart from the case of β-hCG in the SGA <37 which was decreased but did 
not reach significance.  
 
Serum PLGF was measured in 1,869 Non-SGA and 274 SGA cases and was found 
to be significantly reduced in all three SGA groups. A graded response was observed 
with the lowest mean values in the SGA<37 group. 
 









Serum PP13 was measured in 877 Non-SGA and 173 SGA cases and was found to 
be significantly reduced in all three SGA groups. Again a graded response was 
observed with the lowest mean values in the SGA<37 group. 
 
Serum ADAM12 was measured in 830 Non-SGA cases and 168 SGA cases. It was 
also found to be significantly reduced in all three SGA groups with the lowest values 
in the SGA<37 group. 
 
Serum sENG was measured in 200 non-SGA cases and 100 SGA cases. There was 
no significant difference between SGA and controls (p = 0.087). Also, no difference 
was detected between the SGA<37 group and controls.  
 
Maternal FT3, FT4 and TSH were previously measured in 3,592 non-SGA cases and 
as part of this study in 212 SGA cases. There were no significant differences between 
any of the SGA groups and controls (p=0.543).









Table 5.1 Median and interquartile range (IQR) of PAPP-A, free β-hCG, PLGF, PP13, 






Non-SGA All SGA SGA < 37wks SGA ≥ 37wks 
































































































































Comparisons between the SGA and the non-SGA groups by Mann-Whitney U test. 
Significance level * p < 0.00001, † p < 0.01, ‡ p < 0.025. 











Figure 5.1 Box plot with median, interquartile range and 95% CI for placental plasma 




p < 0.00001 
p < 0.00001 









Figure 5.2 Box plot with median, interquartile range and 95% CI for beta chorionic 
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Figure 5.3 Box plot with median, interquartile range and 95% CI for placental growth 
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Figure 5.4 Box plot with median, interquartile range and 95% CI for placental protein 13 
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Figure 5.5 Box plot with median, interquartile range and 95% CI for ADAM 12 (MoM) in 
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5.3.1 Performance of screening 
 
Only the markers who showed a significant difference between SGA and controls 
were included in the prediction analysis 
 
The DR for Maternal factors plus PAPP-A increased to 25.5% for FPR of 5% and 
37.5% for FPR of 10%. Free β-hCG has a small effect over maternal factors only with 
a DR of 22.4% for FPR of 5% and 34.1% for FPR of 10%. PLGF, PP13, and ADAM12 
show very similar performance with individual detection rates over maternal factors 
only of around 25% for FPR of 5% and 37% for FPR of 10%. Overall detection rate 
with the inclusion of all biochemical markers was 30.2% for FPR of 5% and 42.7% for 
FPR of 10%.  
 
The results were also analysed by stratifying SGA to <37 weeks and >37weeks. The 
detection rate of maternal factors plus all biochemical factors for SGA< 37 weeks was 
50.1% for FPR of 5% and 63.0% for FPR of 10%. The breakdown of screening 
performance is summarized in table 5.2 
 









Table 5.2 Performance of screening for delivery of SGA neonates by maternal factors 
only, maternal serum pregnancy-associated plasma protein-A, free b-human chorionic 
gonadotrophin, placental growth factor, placental protein 13, A Disintegrin And 



























21.0 34.0 23.3 35 20.8 33.9 
Maternal 
factors plus 
      
PAPP-A 25.5 37.5 35.5 47.8 24.5 36.6 
Free β-hCG 22.4 34.1 22.9 34.8 22.4 34.1 
PLGF 25.1 37.0 34.3 46.2 23.9 35.7 
PP13 24.7 37.0 25.9 38.6 24.8 37.1 
ADAM12 25.1 37.3 29.5 42.6 24.7 37.1 
All biochemical 
markers 
30.4 42.7 50.1 63.0 29.0 41.7 
DR = Detection rate; FPR = false positive rate 










This study demonstrates that utilizing biochemical markers of placental function in the 
first trimester improves the prediction of SGA neonates and the effect is more 
pronounced in the SGA <37 group (from 23.3% to 50.1% for FPR of 5%). The data 
confirm the results of previous studies and indicate that, as in the case of PE, in 
pregnancies with SGA in the absence of PE there is evidence of impaired placental 
perfusion and function from the first trimester of pregnancy. Below we discuss in 
details the results of the individual markers examined. 
 
5.4.1 PAPP-A and β-hCG 
 
Previous studies have reported that maternal serum PAPP-A below the 5th percentile 
in early pregnancy could detect 10% to 18% of pregnancies delivering SGA neonates, 
and the reported odds ratios varied between 1.7 and 3.3 (Ong et al., 2000; Smith et 
al., 2002; Yaron et al., 2002; Tul et al., 2003; Dugoff et al., 2004; Smith et al., 2006; 
Canini et al., 2008; Spencer et al., 2008; Fox et al., 2009; Law et al., 2009; Montanari 
et al., 2009; Pihl et al., 2009). The findings of this study confirm the results of these 
reports that the levels of maternal serum PAPP-A during the first trimester are low in 
women who subsequently deliver small babies. Additionally, serum free β-hCG was 
low in the SGA group. The finding of such an association implies that birth weight is 
predetermined by placental development during the first trimester of pregnancy. It is 
uncertain to what extent genetic factors affect fetal growth through placentation, 
although there is some evidence that imprinted genes play a role in regulating the 
supply of nutrients to the fetus (Angiolini et al., 2006). The gene encoding for insulin-
like growth factor (IGF) is imprinted and IGF is thought to have a key role in the control 
of placental growth and ability to transfer nutrients (Reik et al., 2003). PAPP-A has 
been shown to be a syncytiotrophoblast-derived protease for IGF binding proteins, 









and the cleavage of these proteins by PAPP-A increases the bioavailability of IGF 
(Bonno et al., 1994; Irwin et al., 1999; Lawrence et al., 1999). It is therefore not 
surprising that low serum PAPP-A is associated with a higher incidence of SGA.  
 
Measurement of maternal serum PAPP-A in early pregnancy is in itself not an 
effective method of screening for SGA neonates. Nevertheless, the observation of 
low levels of PAPP-A in euploid pregnancies in the first trimester has led to 
recommendations that such pregnancies should have follow-up scans for monitoring 
fetal growth (Ong et al., 2000; Smith et al., 2002; Yaron et al., 2002; Tul et al., 2003; 
Dugoff et al., 2004; Smith et al., 2006; Canini et al., 2008; Spencer et al., 2008; Fox 
et al., 2009; Law et al., 2009; Montanari et al.,2009; Pihl et al., 2009). Our results 
demonstrate that the PAPP-A-related patient-specific risk for SGA is substantially 
affected by various maternal factors and is modifiable by the addition of the 
measurement of fetal NT. These variables should be taken into account in calculating 
the patient-specific risk and therefore in defining the real need and frequency of 
subsequent growth scans. 
 
5.4.2 PLGF and sENG 
 
As shown in previous studies in normal pregnancies the maternal serum 
concentrations of PlGF increase with gestational age, decrease with maternal weight 
and are higher in Black than in White women. It has also been shown that cigarette 
smokers have increased levels of PlGF and hence the measured concentrations of 
PlGF were also adjusted for smoking before comparing results between the SGA and 
control groups (Akolekar et al., 2008; Poon et al., 2008). The results are in accordance 
with previous data showing low levels of PLFG in SGA pregnancies. A previous study 
examining 40 SGA pregnancies and 80 AGA pregnancies showed an association 
between low PLGF levels and SGA but when corrected for covariates such as race, 









smoking and BMI the significance was lost (Thadhani et al., 2004). In two larger 
studies with appropriate adjustment the association between low PLGF and SGA has 
been shown to be significant with reported ORs of 0.990 (0.980–0.999) and 
0.92(0.87–0.96) (Erez et al., 2008; Smith et al., 2007).  
 
Soluble endoglin was not found to be correlated with the delivery of an SGA neonate 
in our data. Studies have shown changes in sENG in the second and third trimester 
mostly in PE but also in normotensive SGA (Rana et al., 2007; Kim et al., 2009; 
Jeyabalan et al., 2008; Savvidou et al., Stepan et al., 2007). A study among 
normotensive women delivering an SGA neonate showed a small increase in sENG 
levels beginning at 17 through 20 weeks with a large increase at 37 through 42 weeks 
(Levine et al., 2006). When examining sENG in the first trimester studies have 
demonstrated a change in sENG levels in PE cases, albeit much less pronounced 
(Foidart et al., 2010, Lim et al., 2009).  
 
Data on sENG and normotensive SGA in the first trimester are limited with only two 
studies in the literature. Erez et al. did not demonstrate a difference in sENG in the 
first trimester between SGA neonate and AGA controls and only a possible value in 
the longitudinal assessment of this marker between the first and second trimesters 
(Erez et al., 2008). Another study comparing 46 controls with 56 SGA pregnancies in 
the first trimester reports higher levels of sENG in the SGA group (Romero et al., 
2008). We examined a sample of 100 SGA pregnancies with a strict definition of SGA 
(< 5th centile) with appropriate correction for covariates known to affect sENG levels 
in a normal population and failed to show a significant difference between the all-SGA 
groups and controls but also between the severe SGA (<37wks) and controls.  Our 
study is similar in numbers with the study by Erez et al., and shows similar results. In 
similarity with previously reported behaviour of angiogenic related biomarkers the 
effect appears to be more pronounced in cases of PE but in the case of sENG its 









value does not appear to be significant in the prediction of normotensive SGA in the 
first trimester.  
 
Based on the theory of angiogenic/anti-angiogenic imbalance researchers have 
investigated the value of various ratios between pro-angiogenic factors and anti-
angiogenic factors mostly when studying longitudinal changes of these markers at 
different gestations with weakly positive results (Romero et al., 2008; Erez et al., 
2008). However, with a focus on a screening algorithm applied in a one-stop first-
trimester visit the value of longitudinal assessment becomes less relevant.    
 
5.4.3 PP13 and ADAM12 
 
PP13 and ADAM 12, both placental products, were found to be reduced in the SGA 
group with the highest effect in the SGA<37wks group. The results are in keeping with 
previous studies (Cowans et al., 2008; Chafez et al., 2007; Matwejew et al., 2010, 
Poon et al., 2008; Cowans et al., 2007). ADAM12 demonstrated a better predictive 
value than PP13 however both markers showed a good correlation with serum PAPP-
A (r=0.513, p<0.0001 and r=0.381, p<0.0001). Both markers appear to have a small 
additional benefit in the overall prediction over PAPP-A. The utilization will likely 
depend on the availability of these markers from concurrent use in the PE algorithm 
(Akolekar et al., 2011).   
 
5.4.4 Thyroid Hormones 
 
In the investigation of thyroid hormones, results show that maternal thyroid function 
at 11-13 weeks’ gestation is not significantly different from those delivering 
appropriately grown neonates and there is no evidence that in the SGA group the 
incidence of impaired thyroid function is increased. A previous screening study in 









which maternal thyroid function was assessed at 15-18 weeks’ gestation reported that 
there was no significant difference in mean birth weight between euthyroid 
pregnancies and those with subclinical hypothyroidism (Allan et al., 2000). In contrast, 
a case-control study reported that the mean birth weight in pregnancies with 
subclinical hypothyroidism was significantly lower than in euthyroid controls (Blazer 
et al., 2003). Another screening study before 20 weeks reported that the incidence of 
neonates with birth weight below 2.5 Kg was not significantly different between 
euthyroid pregnancies and those with subclinical hypothyroidism (Casey et al., 2007). 
However, use of mean birth weight or a cut-off in birth weight without appropriate 
adjustments for gestation are not appropriate for the investigation of thyroid function 
on fetal growth.  
 
The strengths of our study are first, examination of a large number of appropriately 
documented cases of SGA and normal controls, secondly, use of normal ranges of 
thyroid function corrected for maternal characteristics, including age, racial origin and 
body mass index (Ashoor et al., 2010a), and thirdly, assessment of thyroid function 
in the first-trimester of pregnancy providing the option for therapeutic interventions in 
future studies to determine if the incidence of SGA can be reduced. The weakness of 
the study was its cross-sectional nature, which did not allow longitudinal assessment 
of thyroid function from early pregnancy to the development of SGA.  
 
The findings that firstly, SGA is not associated with maternal thyroid hypofunction and 
secondly, that there is no correlation between gestation at delivery and TSH, FT3 or 
FT4 suggest that the results of in vitro studies concerning the role of thyroid hormones 
on trophoblast proliferation and invasion (Barber et al., 2005; Oki et al., 2004) may 
not be clinically relevant. Histological studies reported that impaired placentation is 
observed in association with PE with or without SGA and in about half of pregnancies 
with SGA in the absence of PE (Brosens et al., 1977). However, Doppler studies of 









the uterine arteries documented that the incidence of high impedance to flow in 
pregnancies with PE depends on the gestational age at the onset of the disease. The 
uterine artery PI was above the 95th percentile in 82% of those that developed PE 
requiring delivery before 34 weeks (early-PE) and in 40% of those delivering at or 
after 34 weeks (late-PE) (Yu et al., 2008). Similarly, in SGA without PE high PI was 
observed in 44% of those that delivered before 34 weeks and in 10% of those 
delivering at or after 34 weeks. Although the basis of the possible association 
between hypothyroidism, PE and SGA was the suggested role of thyroid hormones 
in promoting placentation and trophoblastic invasion, we previously found that thyroid 
hypofunction is observed in pregnancies developing late- rather than early-PE 
(Ashoor et al., 2010b). We therefore suggested that the association is unlikely to be 
mediated by impaired trophoblastic invasion but rather by a metabolic derangement 
with increased insulin resistance, which is thought to underlie late-PE (Egbor et al., 
2006; Moldenhauer et al., 2003; Bosio et al., 1999; D’Anna et al., 2006).  
 
To conclude, in pregnancies delivering SGA neonates maternal thyroid function at 
11-13 weeks’ gestation is not impaired. Consequently, irrespective of the possible 
effect of thyroid hormones on placentation, hypothyroidism does not have a significant 
contribution to the incidence of SGA neonates.  
 
5.5 CONCLUSION 
In conclusion, we report on a variety of markers (PAPP-A, PLGF, ADAM12 and PP13) 
that show promising performance in the prediction of SGA in the first trimester along 
with their performance in a combined predictive model. We demonstrate a significant 
increase in the detection rate of SGA from the predictive model utilizing only maternal 
factors (From 21% to 30.4% for all SGA for FPR of 5%). We also report on a variety 
of markers, with conflicting results in the existing literature that did not demonstrate a 









value in early screening (sENG, TSH, FT3, and FT4). In the next chapter of this thesis, 
we examine the value of these biochemical markers in combination with maternal 
history and biophysical markers in the prediction of the delivery of an SGA neonate. 
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CHAPTER 6. PREDICTION OF SGA NEONATES FROM 
BIOPHYSICAL AND BIOCHEMICAL MARKERS AT 11-13 




Objective To develop a model for prediction of small-for-gestational age (SGA) 
neonates in the absence of preeclampsia (PE) based on maternal factors and 
biochemical markers at 11-13 weeks’ gestation. 
 
Method Screening study in 1,536 SGA and 31,314 non-SGA pregnancies based on 
maternal characteristics, fetal nuchal translucency (NT) thickness, serum pregnancy-
associated plasma protein-A (PAPP-A) and free b-human chorionic gonadotrophin 
(β-hCG), mean arterial pressure (MAP), uterine pulsatility index (PI) in combination 
with case controlled studies of maternal serum concentration of placental growth 
factor (PLGF), placental protein 13 (PP13) and A Disintegrin And Metalloprotease 
(ADAM12).   Regression analysis was used to develop a model for the prediction of 
SGA. 
 
Results At a false positive rate of 10%, the estimated detection rate by a combination 
of maternal factors and biophysical and biochemical markers at 11-13 weeks was 
73% for SGA requiring delivery before 37 weeks and 46% for those delivering at term. 
 
Conclusion Half of pregnancies with SGA neonates in the absence f PE could 
potentially be identified at 11-13 weeks. 
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Screening and management of placental insufficiency with or without PE has proven 
to be one of the great challenges of modern obstetric care. With increasing evidence 
placing FGR as one of the main causative factors of stillbirth as well as accumulating 
evidence for metabolic imprinting of FGR fetuses having effects late into adult life, an 
effective algorithm for the early prediction of the pregnancies at risk is essential. In 
the previous chapters, we risk-stratified the pregnant population based on factors 
associated with the delivery of SGA neonates and examined different modalities 
thought to reflect placenta function for their predictive value in detecting SGA in the 
first trimester. In large, results were in accordance with previous studies showing 
individual markers having modest predictive value if used in isolation. For a 5% FPR 
maternal risk factors appeared to predict 21% of SGA fetuses and when combined 
with the use of biophysical markers show a sensitivity of 25.5% while in combination 
with biochemical markers from maternal serum can predict 30.4%.  
 
In similarity with screening protocols for aneuploidies in the first trimester the natural 
conclusion and one that has been proposed by many authors is that a combined 
screening algorithm utilizing all available modalities is likely to be the most successful 
screening method (Breeze & Lees 2007, Zhong et al., 2010, Imdad et al., 2011). If we 
take into consideration that the currently accepted surveillance protocol for the 
screen-positive group is serial growth scans at 28, 32 and 36 weeks of gestation, the 
aim of an effective combined protocol would be not only to achieve the highest 
possible DR but also allow for a FPR which would be sustainable by antenatal care 
providers. A recent update of the RCOG guidance on screening for SGA in pregnancy 
proposes an algorithm that stratifies risk factors based on the Odds ratios of having 
an SGA neonate in combination with selective screening with UAPI at 24 weeks and 
serial ultrasound scans in the high-risk group (figure 1.4, chapter 1). However, the 
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effectiveness of the RCOG algorithm has not been validated with no data in the 
literature on its performance.  In a model that treats each risk factor as an independent 
screening test, the false positive rate in the presence of more than one risk factor are 
cumulative resulting is higher screen positive rates. Authors of the guideline mention: 
“There is insufficient evidence to determine how risk factors relate to each other in 
the individual woman and consequently how these risk factors should be managed. 
This includes abnormal maternal Down syndrome serum markers” (RCOG Green-top 
guideline No. 31). So the need for individualised assessment of mothers at risk of 
having an SGA baby is evident.  
 
Data from screening studies in the first trimester utilizing combined algorithms are 
limited. In a recent study combined the use of PAPP-A, bhCG and NT report a DR of 
55% for FPR of 20% (Papastefanou et al., 2012). A second study combining maternal 
characteristics PLGF and PAPP-A reports a DR of 36.8% for FPR 0f 10% (Poon et 
al., 2008). We perform the largest screening study to date, for the delivery of an SGA 
neonate in the first trimester of pregnancy by using a combination of maternal 
characteristics, biophysical and biochemical markers.  
 
  
6.2 PATIENTS AND METHODS 
 
In this chapter, we analyse data derived from the previous studies with a view to 
producing cumulative values for screening performance by using the combination of 
available markers and examine the intercorrelation between the markers examined. 
 
The data for this study were derived from prospective screening for adverse obstetric 
outcomes in women attending for their routine first-trimester screening hospital visit 
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in pregnancy between March 2006 and September 2009. We record maternal 
characteristics and medical history and perform combined screening for aneuploidies 
by measurement of the fetal crown-rump length (CRL) and NT thickness and maternal 
serum PAPP-A and free β-hCG (Robinson & Fleming 1975; Snijders et al., 1998; 
Kagan et al., 2008). In the second part of the study period, we also measured the 
maternal MAP by automated devices (Poon et al., 2010) and used transabdominal 
colour Doppler ultrasound to visualise the left and right uterine artery, measure the PI 
in each vessel and calculate the mean PI (Plasencia et al., 2007). We performed 
case-control studies for PLGF, PP13, and ADAM12 at 11–13 weeks’ gestation in 
pregnancies complicated by the birth of SGA and non-SGA neonates. Detailed 
methodology is described in the previous chapters.  
 
6.2.1 Statistical analysis 
 
All the biophysical and biochemical parameters were adjusted for maternal 
characteristics as previously described. Markers that were not found to be 
significantly different between non-SGA and SGA cases (sENG, TSH, FT3, FT4) were 
not included in the analysis.  
 
The following steps were used to develop a model for predicting the birth of SGA 
neonates. First, in the total screened population there were 1,536 SGA and 31,314 
non-SGA pregnancies. In each patient, the risk for SGA was calculated using 
multivariate logistic regression analysis of maternal factors as previously described 
[6]. Secondly, gaussian distributions of markers in SGA and non-SGA pregnancies 
were fitted. These fitted distributions define the likelihood ratios for the screening tests 
that can be combined with the prior risk to produce a posterior risk. Third, the maternal 
factors related a priori risks and log 10 MoM values of the biophysical and biochemical 
markers were simulated for 500,000 pregnancies from the SGA populations and the 
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non-SGA distributions. For the markers this involved sampling from the fitted 
multivariate gaussian distributions. For the prior risks, this involved drawing samples, 
with replacement, 500,000 records from the screening samples of SGA and non-SGA 
pregnancies. These records were then used to define maternal factors related a priori 
risks for SGA that were multiplied by the likelihood ratios of the biophysical and 
biochemical markers to derive the a-posterior risks in simulated samples of 500,000 
SGA and 500,000 non-SGA pregnancies. Fifth, the a priori and a posteriori risks in 
the SGA and non-SGA groups were used to calculate the detection rates at fixed false 
positive rates of 5 and 10%. The process of sampling with replacement from the SGA 
and non-SGA screening data means that the modelled screening performance 
reflects the screening population. The samples of 500,000 were chosen to make the 
error resulting from the simulation negligible. The statistical software package SPSS 
16.0 (SPSS Inc., Chicago,Ill., USA) was used for data analyses. Monte-Carlo 
simulations were programmed in R (The R Foundation for Statistical Computing, R 
version 2.11.0, ISBN 3–900051–070–0, http://www.rproject.org). 
 
Regression analysis was used to determine the significance of the interrelations 
between all measured biochemical markers. 
 
6.3 RESULTS 
The total study population included 32,850 cases, were 1,536 (4.7%) were SGA and 
31,314 (95.3%) non-SGA pregnancies. In the SGA group, the maternal weight and 
height were significantly lower, and there was a higher prevalence of women of 
African and Asian racial origin, cigarette smokers and those who had assisted 
conception, a history of chronic hypertension and previous pregnancies with SGA 
neonates (Poon et al., 2010). In the SGA group, compared to the non-SGA group, the 
median MoM uterine artery PI and MAP were increased and serum PAPP-A, free β-
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hCG, PLGF, PP13 and ADAM12 as well as fetal NT were decreased (table 6.1). The 
differences between the SGA and non-SGA groups were greater for the subgroup of 
SGA delivering before 37 weeks (n = 163) than those delivering at or after 37 weeks 
(n = 1,373) for most markers apart from MAP, fetal NT, and serum free β-hCG. The 
inter-correlations between biophysical and biochemical markers in the SGA and 
Non-SGA pregnancies are shown in table 6.3. 
 
The estimated detection rates at fixed false positive rates of 5% and 10% in screening 
by maternal factors only and by combinations of maternal factors with biophysical and 
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Table 6.1 Median and interquartile range (IQR) of uterine artery PI, MAP, Δ-NT thickness, 
PAPP-A, free β-hCG, PLGF, PP13 and ADAM12 in the non-SGA group and in those 




Non-SGA All SGA SGA < 37wks SGA ≥ 37wks 













































































































Comparisons between the SGA and the non-SGA groups by Mann-Whitney U test. 
Significance level * p < 0.00001, † p < 0.01, ‡ p < 0.025. 
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Table 6.2 Performance of screening for delivery of SGA neonates by maternal factors 
only and maternal factors with UAPI, MAP, Δ NT, PAPP-A, free β-hCG, PLGF, PP13, 






















M. Factors 21.0 34.0 23.3 35 20.8 33.9 
M. Factors plus       
UA PI 23.9 35.9 32 44.5 23.1 34.9 
MAP 22.5 34.5 22.6 34.6 22.6 34.6 
NT 21.8 33.9 22.5 34.5 22.0 33.6 
PAPP-A 25.5 37.5 35.5 47.8 24.5 36.6 
Free b-HCG 22.4 34.1 22.9 34.8 22.4 34.1 
PLGF 25.1 37.0 34.3 46.2 23.9 35.7 
PP13 24.7 37.0 25.9 38.6 24.8 37.1 
ADAM12 25.1 37.3 29.5 42.6 24.7 37.1 
Biophysical 
markers 
25.5 37.7 33.7 46.8 24.3 36.8 
Biochemical 
markers 
30.4 42.7 50.1 63.0 29.0 41.7 
All markers 34.3 47.3 60.7 73.2 32.5 45.8 
DR = Detection rate; FPR = False positive rate 
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Figure 6.1 Receiver operating characteristics curves in the prediction of SGA neonates in 
the absence of PE by maternal factors only (– – –) and by a combination of maternal factors, 
uterine artery PI, MAP, fetal NT, maternal serum PAPP-A, free  β-hCG, PLGF, PP13 and ADAM 
( ––––– ). 
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Table 6.3 Inter-correlation between log10 MoM values of uterine artery PI, MAP, PAPP-
A, free β-hCG, PLGF and PP13 and square root ADAM12 MoM and Δ- NT thickness, in 
pregnancies delivering non-SGA and SGA neonates 
Variable Uterine artery PI MAP NT 
 r p r P r p 
Non-SGA 
pregnancies 
      
Uterine artery PI 1.000 - -0.044 <0.0001 -0.015 0.038 
MAP -0.044 <0.0001 1.000 - 0.011 0.233 
NT -0.015 0.038 0.011 0.233 1.000 - 
PAPP-A -0.146 <0.0001 -0.014 0.121 0.010 0.082 
Free β-hCG -0.014 0.055 -0.006 0.464 -0.024 <0.0001 
PLGF -0.116 <0.0001 0.019 0.408 0.043 0.064 
PP13 -0.089 0.009 0.035 0.312 0.090 0.008 
ADAM12 -0.005 0.881 0.077 0.029 0.054 0.121 
SGA pregnancies       
Uterine artery PI 1.000 - -0.152 <0.0001 -0.040 0.182 
MAP -0.152 <0.0001 1.000 - -0.079 0.041 
NT -0.040 0.182 -0.079 0.041 1.000 - 
PAPP-A -0.184 <0.0001 0.001 0.979 0.016 0.536 
Free β-hCG -0.015 0.060 0.055 0.157 -0.023 0.370 
PLGF -0.261 <0.0001 -0.073 0.288 0.082 0.178 
PP13 -0.254 0.001 0.148 0.053 0.026 0.733 
ADAM12 -0.030 0.696 0.043 0.577 -0.028 0.715 
r = Pearson correlation coefficient, p = significant value 
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Table 6.3 (continued) Inter-coofelation between log10 MoM values of uterine artery PI, 
MAP, PAPP-A, free β-hCG, PLGF and PP13 and square root ADAM12 MoM and Δ- NT 
thickness, in pregnancies delivering non-SGA and SGA neonates 
 
PAPP-A Free β-Hcg PLGF PP13 ADAM12 
r p r P r p r P r p 
          
-0.146 <0.0001 -0.014 0.055 -0.116 <0.0001 -0.089 0.009 -0.005  
-0.014 0.121 -0.006 0.464 0.019 0.408 0.035 0.312 0.077  
0.010 0.082 -0.024 <0.0001 0.043 0.064 0.090 0.008 0.054  
1.000 - 0.215 <0.0001 0.317 <0.0001 0.300 <0.0001 0.414  
0.215 <0.0001 1.000 - 0.138 <0.0001 0.378 <0.0001 0.238  
0.317 <0.0001 0.138 <0.0001 1 - 0.037 0.290 0.259  
0.300 <0.0001 0.378 <0.0001 0.037 0.290 1 - 0.413  
0.414 <0.0001 0.238 <0.0001 0.259 <0.0001 0.413 <0.0001 1.000  
          
-0.184 <0.0001 -0.015 0.606 -0.261 <0.0001 -0.254 0.001 -0.030 0.696 
0.001 0.979 0.055 0.157 -0.073 0.288 0.148 0.053 0.043 0.577 
0.016 0.536 -0.023 0.370 0.082 0.178 0.026 0.733 -0.028 0.715 
1.000 - 0.174 <0.0001 0.438 <0.0001 0.381 <0.0001 0.513 <0.0001 
0.174 <0.0001 1.000 - 0.049 0.421 0.444 <0.0001 0.207 <0.0001 
0.438 <0.0001 0.049 0.421 1.000 - 0.054 0.490 0.303 <0.0001 
0.381 <0.0001 0.444 <0.0001 0.054 0.0490 1.000 - 0.404 <0.0001 
0.513 <0.0001 0.207 0.007 0.303 <0.0001 0.404 <0.0001 1.000 - 
  r = Pearson correlation coefficient, p = significant value 
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6.4 DISCUSSION  
This study has demonstrated that an algorithm combining maternal characteristics 
and biophysical and biochemical tests at 11–13 weeks could potentially identify half 
of pregnancies that deliver SGA neonates in the absence of PE, at a 10% false 
positive rate. We used logistic regression analysis to derive the a-priori risk for SGA 
from maternal characteristics in a prospective screening study involving more than 
30,000 pregnancies. The patient-specific a posteriori odds for SGA were then 
calculated by multiplying the a priori odds with the likelihood ratio of a series of 
biophysical and biochemical markers after appropriate adjustments for the inter-
correlations of all markers. 
 
The data confirm the results of previous studies and indicate that, as in the case of 
PE, in pregnancies with SGA in the absence of PE there is evidence of impaired 
placental perfusion and function from the first trimester of pregnancy. However, the 
magnitude of such impairment is considerably less than in PE (Akolekar et al., 2010). 
This is not surprising because, unlike PE which is a pathological disorder, SGA is a 
heterogeneous condition which includes constitutionally small fetuses, at no or 
minimally increased risk of perinatal death and handicap, and growth restricted 
fetuses (FGR) due to impaired placentation, genetic disease or environmental 
damage. In our study, we excluded fetal abnormalities but did not distinguish between 
constitutional SGA and FGR by such measures as performing Doppler studies in the 
third trimester of pregnancy (Wright et al., 2008) because the diagnosis of SGA was 
made retrospectively. Nevertheless, we found that the differences in uterine artery PI 
and serum PAPP-A, PLGF, PP13 and ADAM12 between the SGA and non-SGA 
groups were greater for the subgroup of SGA delivering before 37 weeks than those 
delivering at or after 37 weeks. Since the proportion of FGR to constitutional SGA is 
likely to be higher in the preterm rather than term SGA, our findings imply that the 
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early biophysical and biochemical markers could be identifying the FGR subgroup 
amongst the SGA.  
 
Assessment of the patient-specific risk for SGA at 11–13 weeks is a by-product of 
early screening for aneuploidies. In this hospital visit a series of maternal 
characteristics are recorded because these are essential for the correct interpretation 
of the measured free β-hCG and PAPP-A (Kagan et al., 2008). Additionally, an 
ultrasound scan is performed for examination of the fetal anatomy and assessment 
of markers of aneuploidy. We have shown that the use of an algorithm derived from 
multiple regression analysis of a series of basic maternal characteristics and the 
results of the combined test for aneuploidies can identify 37% of pregnancies that will 
deliver SGA neonates, at a false positive rate of 10% (Poon et al., 2010). We have 
previously advocated that the same ultrasound examination at 11–13 weeks should 
include measurement of uterine artery PI because this in combination with maternal 
characteristics, MAP and biomarkers could identify about 90% of pregnancies that 
will develop PE (Akolekar et al., 2010, Poon et al., 2009). This study has shown that 
inclusion of such additional biochemical and biophysical markers could improve the 
early detection of SGA in the absence of PE to 73% for those requiring delivery before 
37 weeks and 46% for those delivering at term. Early estimation of patient-specific 
risks for SGA could potentially improve pregnancy outcome by shifting antenatal care 
from a series of routine visits to a more individualized approach both in terms of the 
schedule and content of such visits.  
 
Considering the existing antenatal care pathway, use of a first-trimester screening 
algorithm necessitates a surveillance protocol for the high-risk group that currently in 
the United Kingdom is serial growth scans at 28, 32, 36 weeks. This surveillance 
protocol has been shown to perform optimally when applied to a high-risk population 
(Chang et al., 1992; Chauhan et al., 2006). In our attempt to define a high-risk 
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population we have shown that the multifactorial predictive model that we apply in the 
first trimester can risk-stratify the pregnancy population better that any modalities 
applied in isolation. Once a pregnancy has been labelled as high risk and enters the 
close surveillance pathway a combination of biometric measurements, liquor volume, 
and Doppler studies can be used to ascertain whether the fetus is suffering from 
placental insufficiency.  
 
Care must be taken by providers applying such early screening algorithms because 
unlike screening for aneuploidies where diagnostic tests are available immediately; 
the diagnosis of FGR can only be made late in gestation or even after birth. The 
psychological cost for a mother being labelled as “high risk” can be high, could 
potentially increase anxiety throughout pregnancy, might increase hospital 
attendances, result in increased number of CTGs and consequently increased the 
rate of intervention. It is essential that appropriate attention is taken into counselling 
women about the implications of these tests and being able to offer on-going support 
throughout the pregnancy. If our screening algorithm was applied with a 5% FPR then 
the screen-positive group would be 6.4% of the whole population and out of those 
women 74% would deliver AGA babies. Similarly, if the 10% FPR was applied then 
the screen-positive group would be 11.7% and out of those, 81% would be normal. 
For this reason robust evidence of FGR must exist in order to justify medical 




In conclusion, we see that a large proportion of pregnancies that are destined to 
develop an SGA neonate can be predicted in the first trimester by a combined 
screening algorithm. Validation of the findings prospectively and in different 
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populations is required. This algorithm can be made part of the routine screening 
regime of every pregnancy and help shape a more targeted antenatal care plan for 
the subsequent gestation.    
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CHAPTER 7. FUTURE STUDIES 
 
 
At the time of publication, our study provided a comprehensive evaluation of the most 
promising markers of fetal growth restriction. Factors that increase the validity of our 
results include the fact that we examined a large low-risk population from which we 
derived our own birthweight centiles. In addition, we utilised validated and quality 
controlled techniques for obtaining the measurements of the ultrasound and 
biochemical markers which make the effects demonstrated more reliable. 
 
Our findings agree with previous studies in that no individual marker appears to 
perform well in detecting SGA in pregnancy. The combination of markers was able to 
detect around 50% of cases of SGA for a FPR of 10% but showed improved detection 
rates for the preterm group.  
 
Placental disease and its different manifestations represent a complex and varied 
pathophysiological process which is not yet fully understood. Looking into the future 
there are certain areas that progress is likely to be observed and will be briefly 
discussed below.  
 
7.1 IMPROVED DEFINITION OF FGR 
 
As discussed previously, one of the reasons of the variable and sometimes poor 
performance of screening algorithms for FGR lies within the heterogeneity of the 
definition of the outcome measure. Commonly an SGA fetus will be used as a proxy 
for FGR but not all SGA fetuses will suffer from true FGR and some fetuses which do 
not fall below the centile threshold for the definition of SGA might be actually suffering 
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from growth restriction. A definition of the outcome measure incorporating evidence 
of placental disease in combination with a reduction in growth is likely to represent 
better the affected population and hence an improved performance of the screening 
algorithm might be able to be demonstrated. A recent attempt at standardisation of 
the definition of FGR was performed via a Delphi procedure. The Delphi procedure 
aims for refinement of opinions by participating experts, while minimizing confounding 
factors present in other group response methods (Sinha et al., 2011).  The definition 
of FGR was separated into early (<32 weeks) and late (>32 weeks) and criteria were 
based on prenatal ultrasound biometry plus Doppler indices (Gordijn et al., 2016). 
The exact definitions are presented in table (7.1). 
 
In a screening study performed the same year the performance of an algorithm 
utilising maternal characteristics, biophysical parameters and biochemical markers in 
the first trimester of pregnancy was compared when the outcome measure was 
defined as the birth of an SGA fetus <10th centile versus an antenatal definition 
including EFW <10th plus Doppler evidence of placental insufficiency. Results showed 
a significantly improved definition of the model utilising the improved FGR definition 
(AUC 0.78 vs 0.68, p<0.001) thus demonstrating that there is scope for improvement 
of first-trimester prediction if FGR is optimally defined. 
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Table 7.1 Definitions of FGR from Delphi procedure (Gordijn et al., 2016).  
 
Definition of early FGR (<32 weeks of gestation): either  
 
1. Abdominal circumference below the 3rd centile OR estimated fetal weight below 
the 3rd centile OR absent end-diastolic flow in the umbilical artery 
OR 
2. Both of the following 
 Estimated fetal weight or abdominal circumference below the 10th centile 
AND 
 Pulsatility index of the uterine artery above the 95th centile OR pulsatility 
index in the umbilical artery above the 95th centile. 
 
Definition of late FGR (≥32 weeks of gestation): 
 
1. Abdominal circumference below the 3rd centile, or estimated fetal weight below 
the 3rd centile 
OR 
2. At least two out of three of the following: 
 Abdominal circumference below the 10th centile OR estimated fetal weight 
below the 10th centile 
 Abdominal circumference OR estimated fetal weight crossing centiles >2 
quartiles 
 Cerebro-placental ratio below the 5th centile OR pulsatility index in the 






7. FUTURE STUDIES 








7.2 DISCOVERY OF NEW BIOMARKERS OF PLACENTAL DISEASE 
 
There is no doubt that a marker that can demonstrate an increased risk of placental 
disease before the development of symptoms would be of great interest with regards 
to patient selection. Traditionally techniques such as enzyme-linked immunosorbent 
assay (ELISA), western blot, immunostaining and polymerase chain reaction (PCR) 
have been used to identify and compare proteins derived by pathophysiological 
pathways that are thought to have relevance to the disease in question (Law et al., 
2015). Due to the highly complex nature of the disease process, it is likely that multiple 
markers will perform better that a single one and hence improved techniques for 
identification of proteins are being increasingly employed. Proteomics research, the 
analysis of the entire set of proteins of a biological system is such an emerging 
technique. It utilises Mass spectrometry in combination with a variety of other 
separation tools to analyse simultaneously hundreds of proteins (Sydor & Nock 2003, 
Law et al., 2015, Hernandez-Nunez & Valdes-Yong, 2015). In one study high-
throughput analysis of proteins in maternal plasma in women with PET and/or FGR 
was performed that identified 166 different proteins between groups including 
previously undetected proteins. Furthermore, it demonstrated differences in protein 
levels between isolated PET and PET associated with FGR (Auer et al., 2009).  Few 
other studies applying proteomic techniques in a variety of tissues such as placentas, 
amniotic fluid or umbilical cord blood obtained from fetuses affected by FGR have 
demonstrated differences between protein profiles when compared to controls 
(Shehab et al., 2009, karamessinis et al., 2008, Cecconi et al., 2011, Wolter et al., 
2012). These potential biomarkers need to be validated in clinical studies with the 
hope that they could be integrated into a screening algorithm.  
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7.3 ASPIRIN FOR THE PREVENTION OF PREECLAMPSIA AND FETAL 
GROWTH RESTRICTION 
 
Preeclampsia and fetal growth restriction being mostly unexplained with regards to 
their pathophysiological mechanisms have suffered from an outright absence of any 
effective preventive or therapeutic interventions that could potentially alter the course 
of the disease, short of delivery of the placenta. The drug with the best evidence to 
date is Aspirin. One meta-analysis on the use of Aspirin has reported a reduction in 
rates of both PET (RR 0.47) and FGR (RR 0.44) (Bujold et al., 2010). The strongest 
effect has been demonstrated when Aspirin was administered before 16 weeks of 
gestation and the highest reduction was in women who suffered from preterm PE 
(Roberge et al., 2012). It is most likely that an effect will be demonstrated if Aspirin is 
given to a high-risk population and hence applying an algorithm in the first trimester 
of pregnancy will facilitate the selection of a high-risk group for subsequent 
randomisation. A large multicentre randomised controlled trial is registered with the 
aim of testing the use of Aspirin in women found to be high risk for PET by using a 
first-trimester screening algorithm (O'Gorman et al., 2016). The screening algorithm 
involves the same markers as the SGA algorithm in this thesis and if results are 
promising it is possible that further investigation will extend to women from the risk of 
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In conclusion, the future looks promising with regards to improvement in the 
management of placental diseases in pregnancy and a hope for an effective 
therapeutic intervention. Our study at the time set a benchmark on the prediction of 
SGA fetuses in the first trimester by utilising the most extensive complement of 
predictive markers. Our algorithm while not accurate enough to be applied to clinical 
practice has demonstrated that a standardised and quality controlled process of 
multifactorial assessment of pregnant women in the first trimester of pregnancy is a 
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